Franklin Strategic Series

Transcription

1 Semiannual Report and Shareholder Letter October 31, 2017 Franklin Strategic Series Franklin Biotechnology Discovery Fund Franklin Natural Resources Fund Sign up for electronic delivery at franklintempleton.com/edelivery

2 Franklin Templeton Investments Gain From Our Perspective At Franklin Templeton Investments, we re dedicated to one goal: delivering exceptional asset management for our clients. By bringing together multiple, world-class investment teams in a single firm, we re able to offer specialized expertise across styles and asset classes, all supported by the strength and resources of one of the world s largest asset managers. This has helped us to become a trusted partner to individual and institutional investors across the globe. Dear Shareholder: During the six months ended October 31, 2017, mostly upbeat economic data, improved US corporate earnings and a supportive monetary policy were positives for US securities markets. At its June meeting, the US Federal Reserve (Fed) increased its target range for the federal funds rate a quarter point to 1.00% 1.25%. Despite low inflation, the Fed made this decision amid signs of a strengthening labor market and moderately rising economic activity. The 10-year US Treasury yield began the period at 2.29% and ended the period at 2.38%. In this environment, US stocks, as measured by the Standard & Poor s 500 Index, generated a +9.10% total return for the six-month period. 1 We are committed to our long-term perspective and disciplined investment approach as we conduct a rigorous, fundamental analysis of securities with a regular emphasis on investment risk management. We believe active, professional investment management serves investors well. We also recognize the important role of financial advisors in today s markets and encourage investors to continue to seek their advice. Amid changing markets and economic conditions, we are confident investors with a well-diversified portfolio and a patient, long-term outlook should be well positioned for the years ahead. discussion about investment decisions during the period. Please remember all securities markets fluctuate, as do mutual fund share prices. We thank you for investing with Franklin Templeton, welcome your questions and comments, and look forward to serving your future investment needs. Sincerely, Edward B. Jamieson President and Chief Executive Officer Investment Management Franklin Strategic Series This letter reflects our analysis and opinions as of October 31, 2017, unless otherwise indicated. The information is not a complete analysis of every aspect of any market, country, industry, security or fund. Statements of fact are from sources considered reliable. In addition, Franklin Strategic Series semiannual report includes more detail about prevailing conditions and a 1. Source: Morningstar See for additional data provider information. Not FDIC Insured May Lose Value No Bank Guarantee franklintempleton.com Not part of the semiannual report 1

3 Contents Semiannual Report Economic and Market Overview... 3 Franklin Biotechnology Discovery Fund... 4 Franklin Natural Resources Fund... 9 Financial Highlights and Statements of Investments Financial Statements Notes to Financial Statements Shareholder Information Visit franklintempleton.com for fund updates, to access your account, or to find helpful financial planning tools. 2 Semiannual Report franklintempleton.com

4 Semiannual Report Economic and Market Overview The US economy grew during the six months under review. The economy grew faster in 2017 s third quarter than in the second quarter, driven by consumer spending, inventory investment, business investment and exports. The manufacturing and services sectors expanded during the period. The unemployment rate decreased from 4.4% in April 2017 to 4.1% at period-end. 1 Monthly retail sales were volatile during the period. Annual inflation, as measured by the Consumer Price Index, decreased from 2.2% in April 2017 to 2.0% at period-end. 1 At its June meeting, the US Federal Reserve (Fed) raised its target range for the federal funds rate 0.25% to 1.00% 1.25%, amid signs of a growing US economy, strengthening labor market and improving business spending. At its July and September 2017 meetings, the Fed kept its target range unchanged. Furthermore in September, the Fed mentioned that it would begin implementing its balance sheet reduction in October. The minutes of the Fed s September meeting released in October suggested that many committee members were concerned that low inflation readings this year might not be transitory and could be more persistent than expected. US equity markets rose during the period, benefiting from mostly upbeat economic data and better US corporate earnings. The markets were also supported by investor optimism arising from Emmanuel Macron s victory in France s presidential election, comments from the US Fed chair indicating optimism about the US economy and the likelihood of gradual rate hikes, and the Senate s approval of a budget plan that raised expectations for tax reforms. However, geopolitical tensions in the Korean peninsula and uncertainty about President Trump s ability to implement reforms curbed market sentiment. The broad US stock market, as measured by the Standard & Poor s 500 Index, generated +9.10% total return for the period. 2 The foregoing information reflects our analysis and opinions as of October 31, The information is not a complete analysis of every aspect of any market, country, industry, security or fund. Statements of fact are from sources considered reliable. 1. Source: Bureau of Labor Statistics. 2. Source: Morningstar. See for additional data provider information. franklintempleton.com Semiannual Report 3

5 Franklin Biotechnology Discovery Fund This semiannual report for Franklin Biotechnology Discovery Fund covers the period ended October 31, Your Fund s Goal and Main Investments The Fund seeks capital appreciation by investing at least 80% of its net assets in securities of biotechnology companies and discovery research firms located in the US and other countries. Performance Overview The Fund s Class A shares delivered a +2.16% cumulative total return for the six months under review. In comparison, the NASDAQ Biotechnology Index, which tracks US and international-based biotechnology stocks, generated a +5.88% total return. 1 Also in comparison, the Standard & Poor s 500 Index (S&P 500 ), which is a broad measure of the US stock market, produced a +9.10% total return. 1 Finally, domestic and international-based stocks, as measured by the NASDAQ Composite Index, posted a % total return. 1 You can find the Fund s long-term performance data in the Performance Summary beginning on page 6. Performance data represent past performance, which does not guarantee future results. Investment return and principal value will fluctuate, and you may have a gain or loss when you sell your shares. Current performance may differ from figures shown. For most recent month-end performance, go to franklintempleton.com or call (800) Investment Strategy We are research-driven, fundamental investors, pursuing a growth strategy. As bottom-up investors focusing primarily on individual securities, we choose companies that have identifiable drivers of future earnings growth and that present, in our opinion, the best trade-off between earnings growth, business and financial risk, and valuation. We rely on a team of analysts to help provide in-depth industry expertise and use both qualitative and quantitative analysis to evaluate companies for distinct and sustainable competitive advantages likely to lead to growth in earnings and/or share price. Competitive advantages, such as a particular product niche, proven Portfolio Composition Based on Total Net Assets as of 10/31/17 Biotechnology Pharmaceuticals Life Sciences Tools & Services Short-Term Investments & Other Net Assets technology, sound financial position and strong management, are all factors we believe may contribute to strong growth potential. Manager s Discussion 9.5% 4.7% 1.5% 84.3% During the six months under review, the biotechnology industry experienced significant volatility in response to uncertainty about the future of the Affordable Care Act. Please keep in mind that volatility is not uncommon in the biotechnology industry, and we seek to take advantage of short-term volatility by initiating positions or adding to existing holdings in companies we believe are undervalued. Key contributors to the Fund s absolute performance during the reporting period included Puma Biotechnology, 2 Vertex Pharmaceuticals and Kite Pharma. 3 Puma Biotechnology, a development stage biopharmaceutical company, bolstered results as it received FDA approval for its early-stage breast cancer treatment drug Nerlynx and launched the medication in July. Puma s stock performed well after we purchased it during the period, as early feedback from physicians suggested a fast launch trajectory. Vertex Pharmaceuticals engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. In July, the company announced positive results from its triple combination studies in cystic fibrosis patients. Vertex was studying the combination of three new experimental drugs on top of its two approved drugs, tezacaftor and ivacaftor, in a patient population where those two approved drugs alone had minimal efficacy. We believe this opened up a 1. Source: Morningstar. The indexes are unmanaged and include reinvestment of any income or distributions. They do not reflect any fees, expenses or sales charges. One cannot invest directly in an index, and an index is not representative of the Fund s portfolio. 2. Not part of the index. 3. Not held at period-end. The dollar value, number of shares or principal amount, and names of all portfolio holdings are listed in the Fund s Statement of Investments (SOI). The SOI begins on page Semiannual Report franklintempleton.com

6 FRANKLIN BIOTECHNOLOGY DISCOVERY FUND significant new patient population for Vertex. Clinical-stage biopharmaceutical company firm Kite Pharma benefited from its acquisition by Gilead at a significant premium. The company develops and commercializes novel cancer immunotherapy products. In contrast, key detractors from the Fund s absolute performance included Axovant Sciences, 2 Tesaro and Celgene. Axovant Sciences, a clinical-stage biopharmaceutical company, hindered results due to a failed Phase 3 trial for its investigational Alzheimer s disease drug intepirdine in September. This was the lead program for Axovant and the primary value driver for the company. Oncology-focused biopharmaceutical company Tesaro experienced weak performance as early reports suggested that tolerability of its ovarian cancer treatment drug Zejula was an issue and physicians favored AstraZeneca s Lynparza. Merck 4 formed a strategic collaboration with AstraZeneca 4 to develop Lynparza in combination with Merck s drugs, becoming a formidable competitor. Biotechnology firm Celgene halted Phase 3 clinical trials for its Crohn s disease drug due to a lack of efficacy. Additionally, Celgene s third quarter results were disappointing as revenues for its psoriasis medication Otezla came in significantly below expectations due to increased competition and discounting. The company also reduced long-term guidance. Thank you for your continued participation in Franklin Biotechnology Discovery Fund. We look forward to serving your future investment needs. Evan McCulloch, CFA Lead Portfolio Manager Steven Kornfeld, CFA Top 10 Holdings 10/31/17 Company Sector/Industry % of Total Net Assets Celgene Corp. 7.5% Biotechnology Alexion Pharmaceuticals Inc. 7.4% Biotechnology Incyte Corp. 5.3% Biotechnology Biogen Inc. 5.3% Biotechnology Illumina Inc. 4.7% Life Sciences Tools & Services Regeneron Pharmaceuticals Inc. 4.6% Biotechnology Gilead Sciences Inc. 4.6% Biotechnology Vertex Pharmaceuticals Inc. 4.2% Biotechnology Neurocrine Biosciences Inc. 3.9% Biotechnology Clovis Oncology Inc. 3.5% Biotechnology The foregoing information reflects our analysis, opinions and portfolio holdings as of October 31, 2017, the end of the reporting period. The way we implement our main investment strategies and the resulting portfolio holdings may change depending on factors such as market and economic conditions. These opinions may not be relied upon as investment advice or an offer for a particular security. The information is not a complete analysis of every aspect of any market, country, industry, security or the Fund. Statements of fact are from sources considered reliable, but the investment manager makes no representation or warranty as to their completeness or accuracy. Although historical performance is no guarantee of future results, these insights may help you understand our investment management philosophy. Portfolio Management Team CFA is a trademark owned by CFA Institute. 4. Not a Fund holding. See for additional data provider information. franklintempleton.com Semiannual Report 5

7 FRANKLIN BIOTECHNOLOGY DISCOVERY FUND Performance Summary as of October 31, 2017 The performance table does not reflect any taxes that a shareholder would pay on Fund dividends, capital gain distributions, if any, or any realized gains on the sale of Fund shares. Total return reflects reinvestment of the Fund s dividends and capital gain distributions, if any, and any unrealized gains or losses. Your dividend income will vary depending on dividends or interest paid by securities in the Fund s portfolio, adjusted for operating expenses of each class. Capital gain distributions are net profits realized from the sale of portfolio securities. Performance as of 10/31/17 1 Cumulative total return excludes sales charges. Average annual total return includes maximum sales charges. Sales charges will vary depending on the size of the investment and the class of share purchased. The maximum is 5.75% and the minimum is 0%. Class A: 5.75% maximum initial sales charge; Advisor Class: no sales charges. For other share classes, visit franklintempleton.com. Share Class Cumulative Total Return 2 Average Annual Total Return 3 A 6-Month +2.16% -3.71% 1-Year % % 5-Year % % 10-Year % % Advisor 4 6-Month +2.29% +2.29% 1-Year % % 5-Year % % 10-Year % % Performance data represent past performance, which does not guarantee future results. Investment return and principal value will fluctuate, and you may have a gain or loss when you sell your shares. Current performance may differ from figures shown. For most recent month-end performance, go to franklintempleton.com or call (800) See page 7 for Performance Summary footnotes. 6 Semiannual Report franklintempleton.com

8 FRANKLIN BIOTECHNOLOGY DISCOVERY FUND PERFORMANCE SUMMARY Total Annual Operating Expenses 5 Share Class With Waiver Without Waiver A 1.04% 1.06% Advisor 0.79% 0.81% Each class of shares is available to certain eligible investors and has different annual fees and expenses, as described in the prospectus. All investments involve risks, including possible loss of principal. The Fund is a nondiversified fund that concentrates in a single sector, which involves risks such as patent considerations, product liability, government regulatory requirements, and regulatory approval for new drugs and medical products. Biotechnology companies often are small and/or relatively new. Smaller companies can be particularly sensitive to changes in economic conditions and have less certain growth prospects than larger, more established companies and can be volatile, especially over the short term. The Fund may also invest in foreign companies, which involve special risks, including currency fluctuations and political uncertainty. The Fund is actively managed but there is no guarantee that the manager s investment decisions will produce the desired results. The Fund s prospectus also includes a description of the main investment risks. 1. The Fund has a fee waiver associated with any investment it makes in a Franklin Templeton money fund and/or other Franklin Templeton fund, contractually guaranteed through 8/31/18. Fund investment results reflect the fee waiver; without this waiver, the results would have been lower. 2. Cumulative total return represents the change in value of an investment over the periods indicated. 3. Average annual total return represents the average annual change in value of an investment over the periods indicated. Return for less than one year, if any, has not been annualized. 4. Effective 9/1/09, the Fund began offering Advisor Class shares, which do not have sales charges or a Rule 12b-1 plan. Performance quotations for this class reflect the following methods of calculation: (a) For periods prior to 9/1/09, a restated figure is used based upon the Fund s Class A performance, excluding the effect of Class A s maximum initial sales charge, but reflecting the effect of the Class A Rule 12b-1 fees; and (b) for periods after 9/1/09, actual Advisor Class performance is used reflecting all charges and fees applicable to that class. Since 9/1/09 (commencement of sales), the cumulative and average annual total returns of Advisor Class shares were % and %. 5. Figures are as stated in the Fund s current prospectus and may differ from the expense ratios disclosed in the Your Fund s Expenses and Financial Highlights sections in this report. In periods of market volatility, assets may decline significantly, causing total annual Fund operating expenses to become higher than the figures shown. franklintempleton.com Semiannual Report 7

9 FRANKLIN BIOTECHNOLOGY DISCOVERY FUND Your Fund s Expenses As a Fund shareholder, you can incur two types of costs: (1) transaction costs, including sales charges (loads) on Fund purchases and redemptions; and (2) ongoing Fund costs, including management fees, distribution and service (12b-1) fees, and other Fund expenses. All mutual funds have ongoing costs, sometimes referred to as operating expenses. The table below shows ongoing costs of investing in the Fund and can help you understand these costs and compare them with those of other mutual funds. The table assumes a $1,000 investment held for the six months indicated. Actual Fund Expenses The table below provides information about actual account values and actual expenses in the columns under the heading Actual. In these columns the Fund s actual return, which includes the effect of Fund expenses, is used to calculate the Ending Account Value for each class of shares. You can estimate the expenses you paid during the period by following these steps (of course, your account value and expenses will differ from those in this illustration): Divide your account value by $1,000 (if your account had an $8,600 value, then $8,600 $1,000 = 8.6). Then multiply the result by the number in the row for your class of shares under the headings Actual and Expenses Paid During Period (if Actual Expenses Paid During Period were $7.50, then 8.6 x $7.50 = $64.50). In this illustration, the actual expenses paid this period are $ Hypothetical Example for Comparison with Other Funds Under the heading Hypothetical in the table, information is provided about hypothetical account values and hypothetical expenses based on the Fund s actual expense ratio and an assumed rate of return of 5% per year before expenses, which is not the Fund s actual return. This information may not be used to estimate the actual ending account balance or expenses you paid for the period, but it can help you compare ongoing costs of investing in the Fund with those of other funds. To do so, compare this 5% hypothetical example for the class of shares you hold with the 5% hypothetical examples that appear in the shareholder reports of other funds. Please note that expenses shown in the table are meant to highlight ongoing costs and do not reflect any transactional costs. Therefore, information under the heading Hypothetical is useful in comparing ongoing costs only, and will not help you compare total costs of owning different funds. In addition, if transactional costs were included, your total costs would have been higher. Share Class Beginning Account Value 5/1/17 Actual (actual return after expenses) Ending Account Value 10/31/17 Expenses Paid During Period 5/1/17 10/31/17 1,2 Hypothetical (5% annual return before expenses) Ending Account Value 10/31/17 Expenses Paid During Period 5/1/17 10/31/17 1,2 Net Annualized Expense Ratio 2 A $1,000 $1, $5.25 $1, $ % C $1,000 $1, $9.05 $1, $ % R6 $1,000 $1, $3.01 $1, $ % Advisor $1,000 $1, $3.98 $1, $ % 1. Expenses are equal to the annualized expense ratio for the six-month period as indicated above in the far right column multiplied by the simple average account value over the period indicated, and then multiplied by 184/365 to reflect the one-half year period. 2. Reflects expenses after fee waivers and expense reimbursements. Does not include acquired fund fees and expenses. 8 Semiannual Report franklintempleton.com

10 Franklin Natural Resources Fund This semiannual report for Franklin Natural Resources Fund covers the period ended October 31, Your Fund s Goal and Main Investments The Fund seeks high total return (total return consists of capital appreciation and current dividend and interest income) by investing, under normal market conditions, at least 80% of its net assets in equity and debt securities of companies that own, produce, refine, process, transport or market natural resources, as well as those that provide related services. Performance Overview The Fund s Class A shares had a -0.40% cumulative total return for the six months under review. In comparison, the Standard & Poor s (S&P ) North American Natural Resources Sector Index, which tracks companies involved in industries such as mining, energy, timber and forestry services, and the production of pulp and paper, generated a +1.57% total return. 1 Also in comparison, the S&P 500, which is a broad measure of the US stock market, generated a +9.10% total return. 1 Please note index performance information is provided for reference and we do not attempt to track any index but rather undertake investments on the basis of fundamental research. The Fund s strategy, which focuses on companies with higher long-term growth potential, differs from the natural resources index s large weighting in income-oriented companies that we believe typically provide more limited opportunities for growth. This difference may occasionally lead to wide performance discrepancies, especially in periods when investors focus on short-term safety and yield or, conversely, when investors focus more heavily on companies with stronger growth prospects and greater commodity price leverage. You can find the Fund s long-term performance data in the Performance Summary beginning on page 13. Performance data represent past performance, which does not guarantee future results. Investment return and principal value will fluctuate, and you may have a gain or loss when you sell your shares. Current performance may differ from figures shown. For most recent month-end performance, go to franklintempleton.com or call (800) Geographic Composition Based on Total Net Assets as of 10/31/17 North America Europe Australia & New Zealand Latin America & Caribbean Middle East & Africa Short-Term Investments & Other Net Assets Investment Strategy We are research-driven, fundamental investors, pursuing a growth strategy. As bottom-up investors focusing primarily on individual securities, we choose companies that have identifiable drivers of future earnings growth and that present, in our opinion, the best trade-off between earnings growth, business and financial risk, and valuation. We rely on a team of analysts to help provide in-depth industry expertise and use both qualitative and quantitative analysis to evaluate companies for distinct and sustainable competitive advantages likely to lead to growth in earnings and/or share price. Competitive advantages, such as a particular product niche, proven technology, sound financial position and strong management, are all factors we believe may contribute to strong growth potential. Sector Overview 2.1% 1.2% 0.8% 0.8% 14.8% 80.3% Global commodity prices were mixed during the six months under review. Although oil and select metals rose, several commodities, such as natural gas and silver, declined. Following an overall downtrend in 2017 s second quarter, global commodities in general benefited from a synchronized recovery across the global economy, firming demand outlooks for a wide range of metals and energy products, a slow-moving Federal Reserve and the support of a weaker US dollar. Industrial commodity prices, in particular, pointed to rising demand, primarily from China, the world s largest consumer of 1. Source: Morningstar. The indexes are unmanaged and include reinvestment of any income or distributions. They do not reflect any fees, expenses or sales charges. One cannot invest directly in an index, and an index is not representative of the Fund s portfolio. The dollar value, number of shares or principal amount, and names of all portfolio holdings are listed in the Fund s Statement of Investments (SOI). The SOI begins on page 27. franklintempleton.com Semiannual Report 9

11 FRANKLIN NATURAL RESOURCES FUND such metals that are integral to its construction and real estate infrastructure. For the declining commodities, oversupply concerns superseded any boost they might have received from consumer demand and the weaker dollar. Portfolio Composition Based on Total Net Assets as of 10/31/17 Oil & Gas Exploration & Production 35.7% Crude oil prices rose during the period and booked their first back-to-back monthly gain of the year in October. Oil benefited from positive global demand trends and output restraint that tightened supply-and-demand fundamentals. This included optimism that major suppliers in the Organization of Petroleum Exporting Countries (OPEC) and partners, including Russia, would extend their previously agreed-upon production curbs. Although crude oil prices declined in the second quarter of 2017, they also recorded a strong rally in June, after US producers appeared to curtail their drilling activity and government data showed a sharp drop in US gasoline supplies as summer demand picked up. During the third quarter of 2017, crude oil prices rose in response to tensions between the US and Iran and potential for disrupted crude exports out of Iraqi Kurdistan, in addition to robust compliance by participants in the OPEC deal to limit production. Overall, US natural gas prices declined during the six months under review, despite a period of stability during the summer months. At period-end, slowing supply growth was helping to balance the market, which was evidenced by inventory builds throughout the month that were generally in line with seasonal expectations. Exports have been key to increased demand recently. An ongoing increase in US exports could accelerate inventory declines as new natural gas export terminals on the Gulf Coast ramp up shipments. In addition, producers began reducing the number of active drilling rigs, indicating that production could struggle to keep pace in Nonetheless, the total US rig count increased for the six-month period. Gold prices fluctuated throughout the period, but rose slightly at period-end amid dollar weakness. Among other precious metals, platinum prices declined and palladium prices rose. Silver prices declined slightly, yet the metal s demand in industrial and technical applications such as smartphones and solar panels continued to grow. Gains for industrial metals such as copper, aluminum and zinc were countered by a decline in iron ore at the end of the period. Expectations for increased demand emerged for copper s use in electric vehicles and other manufactured goods at a time when there is a lack of new copper discoveries and limited spending on new copper projects to replace declining production at older mines. Manager s Discussion The economy as a whole was generally supportive of commodities during the six-month period, with signs of Oil & Gas Equipment & Services Integrated Oil & Gas Diversified Metals & Mining Oil & Gas Storage & Transportation Gold Oil & Gas Refining & Marketing Copper Oil & Gas Drilling Other Short-Term Investments & Other Net Assets 7.4% 5.4% 5.3% 4.3% 4.1% 2.7% 1.3% 0.8% 17.8% 15.2% strengthening global economic growth, a weakening US dollar over most of the period and rising commodity prices. However, there were some pockets and periods of weakness. In this environment, the Fund underperformed the S&P North American Natural Resources Sector Index as a result of an overweighting and stock selection in oilfield services, an underweighting in oil and gas refining and marketing (R&M), partially offset by stock selection, and stock selection in gold. A lack of exposure to sectors with limited direct commodity exposure such as paper and packaging also detracted from relative performance. Oilfield services holdings detracted from relative performance as analysts lowered earnings expectations for 2018 despite currently robust operating conditions. Smaller and mid-capitalization companies, offshore companies and companies with non-us exposure suffered the most (such as Superior Energy, Oil States, Oceaneering and Weatherford), while onshore US pure plays performed well. This performance was perplexing to us given a recovery in energy markets in the second half of the period and flat-to-positive performance from oil and gas exploration and production (E&P) and integrated oil 10 Semiannual Report franklintempleton.com

12 FRANKLIN NATURAL RESOURCES FUND Top 10 Holdings 10/31/17 Company Sector/Industry % of Total Net Assets Schlumberger Ltd. 4.2% Oil & Gas Equipment & Services Anadarko Petroleum Corp. 3.6% Oil & Gas Exploration & Production EOG Resources Inc. 3.5% Oil & Gas Exploration & Production Halliburton Co. 3.4% Oil & Gas Equipment & Services Noble Energy Inc. 3.0% Oil & Gas Exploration & Production Suncor Energy Inc. 2.9% Integrated Oil & Gas ConocoPhillips 2.8% Oil & Gas Exploration & Production Concho Resources Inc. 2.8% Oil & Gas Exploration & Production Royal Dutch Shell PLC 2.6% Integrated Oil & Gas Kinder Morgan Inc. 2.5% Oil & Gas Storage & Transportation companies, but we view this as a function of the complexity of predicting oil prices, spending trends and oilfield services earnings in an uncertain environment. R&M benefited from a strong profit margin environment, supported by rising US production, widening price spreads between US and international oil grades (such as WTI/Brent), and strong refining margins driven higher by hurricane disruptions. A lack of exposure to Andeavor and underweightings in Valero and Phillips 66 were the biggest detractors, although an overweighting in HollyFrontier helped to offset these detractors. The Fund s gold holdings suffered from significant declines in relatively small positions in Guyana Goldfields 2 and Tahoe Resources, both of which declined due to company-specific exposure to host-country risks. In contrast, contributors to the Fund s relative performance included overweightings in diversified metals and mining and copper, as well as stock selection in the integrated oil and gas sector, partially offset by an underweighting in the sector. Stock selection in E&P, partially offset by an overweighting in the sector, also helped. Metals markets performed well as the result of tightening supply and demand conditions for several metals, partly driven by China s efforts to curtail pollution and improve profitability in certain segments of their economy (such as coal). Uncertainty related to the longevity of such moves is prevalent, but rising metals prices combined with most mining companies efforts to reduce costs and capital spending over the past several years improved their financial outlook considerably, allowing many to generate free cash flow and pay down or term out debt. Many diversified metals and mining holdings in the Fund appreciated significantly. The same dynamic benefited our copper holdings (formally included in diversified metals and mining). Top contributors to the Fund s relative performance were diversified miners BHP, Glencore and Rio Tinto, and Lundin Mining and Antofagasta in the copper sector. 2 Fund positioning in integrated oil and gas benefited relative performance with a large proportion of investments focused in European-based majors such as Royal Dutch Shell, 2 BP 2 and Total, 2 which all performed well. Generally speaking, European integrateds appeared to us to have lower valuations and higher dividend yields than their US counterparts, and although we remained overweighted, the gaps have closed somewhat after the shares strong relative performance. It is important to recognize the effect of currency movements on the Fund s performance. In general, if the value of the US dollar goes up compared with a foreign currency, an investment traded in that foreign currency will go down in value because it will be worth fewer US dollars. This can have a negative effect on Fund performance. Conversely, when the US dollar weakens in relation to a foreign currency, an investment traded in that foreign currency will increase in value, which can contribute to Fund performance. For the six months ended October 31, 2017, the US dollar declined in value relative to most currencies. As a result, the Fund s performance was positively affected by currency appreciation from the portfolio s significant investment in securities with non-us currency exposure. However, one cannot expect the same result in future periods. Whether the US dollar goes up or weakens compared with foreign currencies, company-specific factors may offset the effects of the currency movements on the value of individual investments and, possibly, the Fund s performance overall. 2. Not part of the index. See for additional data provider information. franklintempleton.com Semiannual Report 11

13 FRANKLIN NATURAL RESOURCES FUND Thank you for your continued participation in Franklin Natural Resources Fund. We look forward to serving your future investment needs. Frederick G. Fromm, CFA Matthew J. Adams, CFA Stephen M. Land, CFA Portfolio Management Team The foregoing information reflects our analysis, opinions and portfolio holdings as of October 31, 2017, the end of the reporting period. The way we implement our main investment strategies and the resulting portfolio holdings may change depending on factors such as market and economic conditions. These opinions may not be relied upon as investment advice or an offer for a particular security. The information is not a complete analysis of every aspect of any market, country, industry, security or the Fund. Statements of fact are from sources considered reliable, but the investment manager makes no representation or warranty as to their completeness or accuracy. Although historical performance is no guarantee of future results, these insights may help you understand our investment management philosophy. 12 Semiannual Report franklintempleton.com

14 FRANKLIN NATURAL RESOURCES FUND Performance Summary as of October 31, 2017 The performance table does not reflect any taxes that a shareholder would pay on Fund dividends, capital gain distributions, if any, or any realized gains on the sale of Fund shares. Total return reflects reinvestment of the Fund s dividends and capital gain distributions, if any, and any unrealized gains or losses. Your dividend income will vary depending on dividends or interest paid by securities in the Fund s portfolio, adjusted for operating expenses of each class. Capital gain distributions are net profits realized from the sale of portfolio securities. Performance as of 10/31/17 1 Cumulative total return excludes sales charges. Average annual total return includes maximum sales charges. Sales charges will vary depending on the size of the investment and the class of share purchased. The maximum is 5.75% and the minimum is 0%. Class A: 5.75% maximum initial sales charge; Advisor Class: no sales charges. For other share classes, visit franklintempleton.com. Share Class Cumulative Total Return 2 Average Annual Total Return 3 A 6-Month -0.40% -6.12% 1-Year +0.85% -4.96% 5-Year % -5.87% 10-Year % -4.59% Advisor 6-Month -0.30% -0.30% 1-Year +1.08% +1.08% 5-Year % -4.49% 10-Year % -3.75% Performance data represent past performance, which does not guarantee future results. Investment return and principal value will fluctuate, and you may have a gain or loss when you sell your shares. Current performance may differ from figures shown. For most recent month-end performance, go to franklintempleton.com or call (800) See page 14 for Performance Summary footnotes. franklintempleton.com Semiannual Report 13

15 FRANKLIN NATURAL RESOURCES FUND PERFORMANCE SUMMARY Total Annual Operating Expenses 4 Share Class With Waiver Without Waiver A 1.06% 1.07% Advisor 0.81% 0.82% Each class of shares is available to certain eligible investors and has different annual fees and expenses, as described in the prospectus. All investments involve risks, including possible loss of principal. Investing in a fund concentrating in the natural resources sector involves special risks, including increased susceptibility to adverse economic and regulatory developments affecting the sector. Smaller companies can be particularly sensitive to changes in economic conditions and have less certain growth prospects than larger, more established companies and can be volatile, especially over the short term. The Fund may also invest in foreign companies, which involve special risks, including currency fluctuations and political uncertainty. The Fund is actively managed but there is no guarantee that the manager s investment decisions will produce the desired results. The Fund s prospectus also includes a description of the main investment risks. 1. The Fund has a fee waiver associated with any investment it makes in a Franklin Templeton money fund and/or other Franklin Templeton fund, contractually guaranteed through 8/31/18. Fund investment results reflect the fee waiver; without this waiver, the results would have been lower. 2. Cumulative total return represents the change in value of an investment over the periods indicated. 3. Average annual total return represents the average annual change in value of an investment over the periods indicated. Return for less than one year, if any, has not been annualized. 4. Figures are as stated in the Fund s current prospectus and may differ from the expense ratios disclosed in the Your Fund s Expenses and Financial Highlights sections in this report. In periods of market volatility, assets may decline significantly, causing total annual Fund operating expenses to become higher than the figures shown. 14 Semiannual Report franklintempleton.com

16 FRANKLIN NATURAL RESOURCES FUND Your Fund s Expenses As a Fund shareholder, you can incur two types of costs: (1) transaction costs, including sales charges (loads) on Fund purchases and redemptions; and (2) ongoing Fund costs, including management fees, distribution and service (12b-1) fees, and other Fund expenses. All mutual funds have ongoing costs, sometimes referred to as operating expenses. The table below shows ongoing costs of investing in the Fund and can help you understand these costs and compare them with those of other mutual funds. The table assumes a $1,000 investment held for the six months indicated. Actual Fund Expenses The table below provides information about actual account values and actual expenses in the columns under the heading Actual. In these columns the Fund s actual return, which includes the effect of Fund expenses, is used to calculate the Ending Account Value for each class of shares. You can estimate the expenses you paid during the period by following these steps (of course, your account value and expenses will differ from those in this illustration): Divide your account value by $1,000 (if your account had an $8,600 value, then $8,600 $1,000 = 8.6). Then multiply the result by the number in the row for your class of shares under the headings Actual and Expenses Paid During Period (if Actual Expenses Paid During Period were $7.50, then 8.6 x $7.50 = $64.50). In this illustration, the actual expenses paid this period are $ Hypothetical Example for Comparison with Other Funds Under the heading Hypothetical in the table, information is provided about hypothetical account values and hypothetical expenses based on the Fund s actual expense ratio and an assumed rate of return of 5% per year before expenses, which is not the Fund s actual return. This information may not be used to estimate the actual ending account balance or expenses you paid for the period, but it can help you compare ongoing costs of investing in the Fund with those of other funds. To do so, compare this 5% hypothetical example for the class of shares you hold with the 5% hypothetical examples that appear in the shareholder reports of other funds. Please note that expenses shown in the table are meant to highlight ongoing costs and do not reflect any transactional costs. Therefore, information under the heading Hypothetical is useful in comparing ongoing costs only, and will not help you compare total costs of owning different funds. In addition, if transactional costs were included, your total costs would have been higher. Share Class Beginning Account Value 5/1/17 Actual (actual return after expenses) Ending Account Value 10/31/17 Expenses Paid During Period 5/1/17 10/31/17 1,2 Hypothetical (5% annual return before expenses) Ending Account Value 10/31/17 Expenses Paid During Period 5/1/17 10/31/17 1,2 Net Annualized Expense Ratio 2 A $1,000 $ $5.84 $1, $ % C $1,000 $ $9.59 $1, $ % R6 $1,000 $ $2.82 $1, $ % Advisor $1,000 $ $4.58 $1, $ % 1. Expenses are equal to the annualized expense ratio for the six-month period as indicated above in the far right column multiplied by the simple average account value over the period indicated, and then multiplied by 184/365 to reflect the one-half year period. 2. Reflects expenses after fee waivers and expense reimbursements. Does not include acquired fund fees and expenses. franklintempleton.com Semiannual Report 15

17 Financial Highlights Franklin Biotechnology Discovery Fund Class A Six Months Ended October 31, 2017 (unaudited) Year Ended April 30, Per share operating performance (for a share outstanding throughout the period) Net asset value, beginning of period... $ $ $ $ $ $ Income from investment operations a : Net investment income (loss) b... (0.32) (0.79) (0.94) (1.09) (1.07) (0.76) Net realized and unrealized gains (losses) (39.39) Total from investment operations (40.33) Less distributions from: Net investment income.... (1.73) (0.07) Netrealizedgains... (4.20) (13.78) (6.67) (8.79) Totaldistributions... (5.93) (13.78) (6.67) (8.79) (0.07) Net asset value, end of period... $ $ $ $ $ $ Total return c % 20.02% (23.55)% 46.81% 30.60% 39.12% Ratios to average net assets d Expenses before waiver and payments by affiliates % 1.04% 0.99% 1.00% 1.10% 1.20% Expenses net of waiver and payments by affiliates % e 1.02% e 0.98% e 1.00% e,f 1.10% e,f 1.20% Netinvestmentincome(loss)... (0.38)% (0.58)% (0.56)% (0.67)% (0.82)% (0.88)% Supplemental data Net assets, end of period (000 s)... $1,153,401 $1,176,687 $1,074,903 $1,601,906 $1,141,890 $653,718 Portfolio turnover rate % 34.12% 22.13% 41.43% 48.70% 33.64% athe amount shown for a share outstanding throughout the period may not correlate with the Statement of Operations for the period due to the timing of sales and repurchases of the Fund s shares in relation to income earned and/or fluctuating fair value of the investments of the Fund. bbased on average daily shares outstanding. c Total return does not reflect sales commissions or contingent deferred sales charges, if applicable, and is not annualized for periods less than one year. dratios are annualized for periods less than one year, except for non-recurring expenses, if any. ebenefit of expense reduction rounds to less than 0.01%. f Benefit of waiver and payments by affiliates rounds to less than 0.01%. 16 Semiannual Report The accompanying notes are an integral part of these financial statements. franklintempleton.com

18 FINANCIAL HIGHLIGHTS Franklin Biotechnology Discovery Fund (continued) Class C Six Months Ended October 31, 2017 (unaudited) Year Ended April 30, a Per share operating performance (for a share outstanding throughout the period) Net asset value, beginning of period... $ $ $ $ $ Income from investment operations b : Net investment income (loss) c... (0.87) (1.81) (2.11) (2.38) (0.34) Net realized and unrealized gains (losses) (38.79) (29.70) Total from investment operations (40.90) (30.04) Less distributions from: Net investment income... (1.29) Netrealizedgains... (4.20) (13.78) (6.67) Totaldistributions... (5.49) (13.78) (6.67) Net asset value, end of period.... $ $ $ $ $ Total return d % 19.14% (24.09)% 45.76% (18.88)% Ratios to average net assets e Expenses before waiver and payments by affiliates % 1.79% 1.71% 1.75% 1.82% Expenses net of waiver and payments by affiliates f % 1.77% 1.70% 1.75% g 1.82% g Netinvestmentincome(loss)... (1.13)% (1.33)% (1.28)% (1.42)% (1.52)% Supplemental data Net assets, end of period (000 s).... $57,334 $53,935 $17,562 $23,051 $5,486 Portfolio turnover rate % 34.12% 22.13% 41.43% 48.70% afor the period March 4, 2014 (effective date) to April 30, bthe amount shown for a share outstanding throughout the period may not correlate with the Statement of Operations for the period due to the timing of sales and repurchases of the Fund s shares in relation to income earned and/or fluctuating fair value of the investments of the Fund. cbased on average daily shares outstanding. d Total return does not reflect sales commissions or contingent deferred sales charges, if applicable, and is not annualized for periods less than one year. eratios are annualized for periods less than one year, except for non-recurring expenses, if any. fbenefit of expense reduction rounds to less than 0.01%. g Benefit of waiver and payments by affiliates rounds to less than 0.01%. franklintempleton.com The accompanying notes are an integral part of these financial statements. Semiannual Report 17

19 FINANCIAL HIGHLIGHTS Franklin Biotechnology Discovery Fund (continued) Class R6 Six Months Ended October 31, 2017 (unaudited) Year Ended April 30, a Per share operating performance (for a share outstanding throughout the period) Net asset value, beginning of period... $ $ $ $ $ Income from investment operations b : Net investment income (loss) c (0.25) (0.32) (0.45) (0.49) Net realized and unrealized gains (losses) (40.28) Total from investment operations (40.60) Less distributions from: Net investment income... (2.30) Netrealizedgains... (4.20) (13.78) (6.67) (8.79) Totaldistributions... (6.50) (13.78) (6.67) (8.79) Net asset value, end of period.... $ $ $ $ $ Total return d % 20.50% (23.24)% 47.40% 34.10% Ratios to average net assets e Expenses before waiver and payments by affiliates % 0.63% 0.60% 0.60% 0.63% Expenses net of waiver and payments by affiliates f % 0.61% 0.59% 0.60% g 0.63% g Netinvestmentincome(loss) % (0.17)% (0.17)% (0.27)% (0.35)% Supplemental data Net assets, end of period (000 s).... $8,872 $8,891 $5,568 $76,436 $50,846 Portfolio turnover rate % 34.12% 22.13% 41.43% 48.70% afor the year May 1, 2013 (effective date) to April 30, bthe amount shown for a share outstanding throughout the period may not correlate with the Statement of Operations for the period due to the timing of sales and repurchases of the Fund s shares in relation to income earned and/or fluctuating fair value of the investments of the Fund. cbased on average daily shares outstanding. d Total return is not annualized for periods less than one year. eratios are annualized for periods less than one year, except for non-recurring expenses, if any. fbenefit of expense reduction rounds to less than 0.01%. g Benefit of waiver and payments by affiliates rounds to less than 0.01%. 18 Semiannual Report The accompanying notes are an integral part of these financial statements. franklintempleton.com

20 FINANCIAL HIGHLIGHTS Franklin Biotechnology Discovery Fund (continued) Advisor Class Six Months Ended October 31, 2017 (unaudited) Year Ended April 30, Per share operating performance (for a share outstanding throughout the period) Net asset value, beginning of period... $ $ $ $ $ $ Income from investment operations a : Net investment income (loss) b... (0.14) (0.46) (0.55) (0.70) (0.69) (0.52) Net realized and unrealized gains (losses) (40.12) Total from investment operations (40.67) Less distributions from: Net investment income.... (2.08) (0.07) Netrealizedgains... (4.20) (13.78) (6.67) (8.79) Totaldistributions... (6.28) (13.78) (6.67) (8.79) (0.07) Net asset value, end of period... $ $ $ $ $ $ Total return c % 20.32% (23.36)% 47.17% 31.02% 39.51% Ratios to average net assets d Expenses before waiver and payments by affiliates % 0.79% 0.75% 0.75% 0.80% 0.91% Expenses net of waiver and payments by affiliates % e 0.77% e 0.74% e 0.75% e,f 0.80% e,f 0.91% Netinvestmentincome(loss)... (0.13)% (0.33)% (0.32)% (0.42)% (0.52)% (0.59)% Supplemental data Net assets, end of period (000 s)... $182,670 $159,894 $93,263 $167,035 $91,012 $25,744 Portfolio turnover rate % 34.12% 22.13% 41.43% 48.70% 33.64% athe amount shown for a share outstanding throughout the period may not correlate with the Statement of Operations for the period due to the timing of sales and repurchases of the Fund s shares in relation to income earned and/or fluctuating fair value of the investments of the Fund. bbased on average daily shares outstanding. c Total return is not annualized for periods less than one year. dratios are annualized for periods less than one year, except for non-recurring expenses, if any. ebenefit of expense reduction rounds to less than 0.01%. f Benefit of waiver and payments by affiliates rounds to less than 0.01%. franklintempleton.com The accompanying notes are an integral part of these financial statements. Semiannual Report 19

21 Statement of Investments, October 31, 2017 (unaudited) Franklin Biotechnology Discovery Fund Country Shares/ Warrants Common Stocks and Other Equity Interests 98.4% Biotechnology 84.2% aacadiapharmaceuticalsinc.... UnitedStates 1,017,000 $ 35,422,110 aacceleronpharmainc.... UnitedStates 166,700 6,501,300 aaimmunetherapeuticsinc... UnitedStates 150,000 4,360,500 aalexionpharmaceuticalsinc... UnitedStates 871, ,235,826 AmgenInc.... UnitedStates 253,900 44,488,358 a AmicusTherapeuticsInc... UnitedStates 933,900 13,298,736 aanaptysbioinc.... UnitedStates 102,470 6,766,094 a,baquinoxpharmaceuticalsinc.... Canada 469,500 5,291,265 a,barcabiopharmainc... UnitedStates 478, ,500 a,c ARCAbiopharmaInc.,wts.,6/16/22... UnitedStates 1,338,619 46,185 a,bargenxse,adr... Netherlands 125,500 2,876,460 aarray BioPharma Inc.... UnitedStates 2,416,900 25,256,605 a AudentesTherapeuticsInc... UnitedStates 139,400 3,706,646 a,b AuriniaPharmaceuticalsInc.... Canada 459,100 2,699,508 aavexisinc... UnitedStates 87,426 9,136,891 aaxovantsciencesltd... UnitedStates 383,734 2,010,766 a BiogenInc... UnitedStates 236,461 73,695,435 a BioMarinPharmaceuticalInc... UnitedStates 410,256 33,677,915 abioverativinc... UnitedStates 134,280 7,586,820 a BluebirdBioInc... UnitedStates 83,600 11,628,760 a CalitheraBiosciencesInc... UnitedStates 275,500 4,435,550 a,b CaraTherapeuticsInc.... UnitedStates 159,600 2,001,384 acelgenecorp.... UnitedStates 1,047, ,755,978 a ChemoCentryxInc... UnitedStates 743,808 4,886,819 a ClovisOncologyInc... UnitedStates 644,100 48,545,817 a Concert Pharmaceuticals Inc..... UnitedStates 263,800 4,497,790 a,bcrisprtherapeuticsag... Switzerland 274,014 5,288,470 acytomxtherapeuticsinc... UnitedStates 125,100 2,502,000 a DecipheraPharmaceuticalsInc... UnitedStates 93,800 1,800,022 a,b DelMarPharmaceuticalsInc... Canada 388, ,228 a,c DelMarPharmaceuticalsInc.,wts.,4/12/22... Canada 291,578 15,270 adynavaxtechnologiescorp.... UnitedStates 368,070 8,097,540 aedgetherapeuticsinc... UnitedStates 889,946 9,664,814 a EnantaPharmaceuticalsInc... UnitedStates 110,500 5,488,535 a EpizymeInc.... UnitedStates 371,700 6,207,390 a ExelixisInc... UnitedStates 765,100 18,966,829 a,dfatetherapeuticsinc... UnitedStates 2,373,777 11,322,916 a G1TherapeuticsInc... UnitedStates 123,000 2,906,490 a,c,eg1therapeuticsinc.,privateplacement... UnitedStates 314,126 7,267,468 GileadSciencesInc... UnitedStates 854,100 64,023,336 aglycomimeticsinc... UnitedStates 670,100 7,706,150 aherontherapeuticsinc.... UnitedStates 1,781,023 27,338,703 a ImmuneDesignCorp... UnitedStates 1,039,227 5,144,174 aimmunogeninc... UnitedStates 1,041,200 6,038,960 aincyte Corp.... UnitedStates 653,200 73,974,900 a,c,eintarciatherapeuticsinc.,dd... UnitedStates 80,195 3,484,900 aiovancebiotherapeuticsinc.... UnitedStates 1,378,100 10,714,727 a Karyopharm Therapeutics Inc.... UnitedStates 652,554 6,662,576 aloxooncologyinc... UnitedStates 94,200 8,116,272 a MacroGenicsInc... UnitedStates 180,200 3,566,158 b MerrimackPharmaceuticalsInc... UnitedStates 140,218 1,646,159 a MerusBV... Netherlands 240,506 3,802,400 Value 20 Semiannual Report franklintempleton.com

22 STATEMENT OF INVESTMENTS (UNAUDITED) Franklin Biotechnology Discovery Fund (continued) Country Shares/ Warrants Value Common Stocks and Other Equity Interests (continued) Biotechnology (continued) aminerva Neurosciences Inc.... UnitedStates 426,800 $ 2,688,840 amoleculartemplatesinc.,wts.,2/12/20... UnitedStates 439,500 a NateraInc... UnitedStates 392,629 4,314,993 aneurocrinebiosciencesinc... UnitedStates 874,300 54,302,773 a,bnightstartherapeuticsplc,adr... UnitedStates 122,000 2,677,900 a,cnorthwestbiotherapeuticsinc.,wts.,2/20/19... UnitedStates 223,880 a,c,e OdonateTherapeuticsLLC,RegD... UnitedStates 93,991 2,799,992 a OvaScienceInc... UnitedStates 250, ,234 apfenexinc... UnitedStates 532,384 1,682,333 a,bproqrtherapeuticsnv... Netherlands 123, ,540 a,b Proteostasis Therapeutics Inc.... UnitedStates 88, ,568 apumabiotechnologyinc... UnitedStates 288,800 36,764,240 a,b RadiusHealthInc... UnitedStates 157,400 5,054,114 aregeneronpharmaceuticalsinc.... UnitedStates 159,109 64,060,466 a REGENXBIOInc... UnitedStates 345,200 10,338,740 a RetrophinInc... UnitedStates 376,194 9,355,945 arhythmpharmaceuticalsinc... UnitedStates 49,300 1,261,094 asagetherapeuticsinc... UnitedStates 113,870 7,205,694 a,b SynlogicInc.... UnitedStates 77,990 1,139,434 a Tesaro Inc.... UnitedStates 320,944 37,155,687 a,btgtherapeuticsinc... UnitedStates 504,000 4,107,600 a VertexPharmaceuticalsInc... UnitedStates 400,800 58,608,984 avtvtherapeuticsinc.,a... UnitedStates 317,100 2,004,072 axencor Inc.... UnitedStates 186,632 3,691,581 a,bzailabltd.,adr... China 93,600 2,528,136 a ZymeworksInc.... Canada 295,900 2,485,560 1,180,766,925 Life Sciences Tools & Services 4.7% ailluminainc... UnitedStates 320,400 65,742,876 Pharmaceuticals 9.5% a AclarisTherapeuticsInc... UnitedStates 583,062 14,698,993 aagiletherapeuticsinc.... UnitedStates 999,100 4,745,725 a,d AlcobraLtd... Israel 1,737,306 2,727,570 a AratanaTherapeuticsInc... UnitedStates 1,102,000 6,314,460 abiopharmx Corp.... UnitedStates 1,991, ,060 a,fbiopharmx Corp., 144A... UnitedStates 1,945, ,681 a,c BioPharmX Corp., wts., 3/29/21... UnitedStates 108,000 3,661 a,c BioPharmX Corp., wts., 11/22/23... UnitedStates 1,679, ,074 a,bcollegiumpharmaceuticalinc... UnitedStates 442,700 4,573,091 acymabaytherapeuticsinc... UnitedStates 547,200 5,050,656 a,begaletcorp... UnitedStates 1,032,677 1,012,023 a FlexPharmaInc.... UnitedStates 170, ,136 afoamixpharmaceuticalsltd... Israel 371,100 2,267,421 agwpharmaceuticalsplc,adr... UnitedKingdom 68,367 7,380,218 a JazzPharmaceuticalsPLC... UnitedStates 97,900 13,855,787 a,bmarinuspharmaceuticalsinc... UnitedStates 831,820 4,608,283 athemedicinesco.... UnitedStates 373,200 10,725,768 a NabrivaTherapeuticsPLC... Ireland 140, ,412 aneostherapeuticsinc... UnitedStates 614,800 6,393,920 a,bnovaninc... UnitedStates 120, ,701 a ParatekPharmaceuticalsInc... UnitedStates 131,500 2,814,100 franklintempleton.com Semiannual Report 21

23 STATEMENT OF INVESTMENTS (UNAUDITED) Franklin Biotechnology Discovery Fund (continued) Country Shares/ Warrants Value Common Stocks and Other Equity Interests (continued) Pharmaceuticals (continued) a,breatapharmaceuticalsinc... UnitedStates 91,000 $ 2,755,480 arevancetherapeuticsinc... UnitedStates 592,200 15,397,200 a,b TherapeuticsMDInc... UnitedStates 2,847,040 13,438,029 azogenixinc... UnitedStates 292,015 10,950, ,603,012 Total Common Stocks and Other Equity Interests (Cost $851,845,195)... 1,379,112,813 Escrows and Litigation Trusts (Cost $2,788,760) 0.1% a,ctrue North Therapeutics Inc., Escrow Account... UnitedStates 759,880 1,346,728 Total Investments before Short Term Investments (Cost $854,633,955)... 1,380,459,541 Short Term Investments 5.2% Money Market Funds (Cost $24,306,864) 1.7% g,h InstitutionalFiduciaryTrustMoneyMarketPortfolio,0.69%... UnitedStates 24,306,864 24,306,864 i Investments from Cash Collateral Received for Loaned Securities (Cost $48,868,987) 3.5% Money Market Funds 3.5% g,h InstitutionalFiduciaryTrustMoneyMarketPortfolio,0.69%... UnitedStates 48,868,987 48,868,987 Total Investments (Cost $927,809,806) 103.7%... 1,453,635,392 Other Assets, less Liabilities (3.7)%... (51,358,838) Net Assets 100.0%... $1,402,276,554 See Abbreviations on page 45. anon-income producing. ba portion or all of the security is on loan at October 31, See Note 1(c). cfair valued using significant unobservable inputs. See Note 11 regarding fair value measurements. dsee Note 9 regarding holdings of 5% voting securities. esee Note 8 regarding restricted securities. fsecurity was purchased pursuant to Rule 144A under the Securities Act of 1933 and may be sold in transactions exempt from registration only to qualified institutional buyers or in a public offering registered under the Securities Act of These securities have been deemed liquid under guidelines approved by the Trust s Board of Trustees. At October 31, 2017, the aggregate value of these securities was $355,681, representing less than 0.1% of net assets. g See Note 3(f) regarding investments in affiliated management investment companies. hthe rate shown is the annualized seven-day yield at period end. isee Note 1(c) regarding securities on loan. 22 Semiannual Report The accompanying notes are an integral part of these financial statements. franklintempleton.com

24 Financial Highlights Franklin Natural Resources Fund Class A Six Months Ended October 31, 2017 (unaudited) Year Ended April 30, Per share operating performance (for a share outstanding throughout the period) Net asset value, beginning of period... $25.11 $25.02 $31.46 $39.79 $33.03 $35.81 Income from investment operations a : Net investment income b c Net realized and unrealized gains (losses)... (0.35) 0.17 (6.55) (8.27) 6.65 (2.86) Total from investment operations... (0.10) 0.37 (6.26) (8.04) 6.84 (2.78) Less distributions from net investment income. (0.28) (0.18) (0.29) (0.08) Net asset value, end of period... $25.01 $25.11 $25.02 $31.46 $39.79 $33.03 Total return d... (0.40)% 1.37% (19.80)% (20.07)% 20.74% (7.76)% Ratios to average net assets e Expenses before waiver and payments by affiliates % 1.06% 1.14% 1.08% 1.07% 1.08% Expenses net of waiver and payments by affiliates % f 1.05% f 1.13% 1.08% f,g 1.07% f,g 1.08% Netinvestmentincome % c 0.79% 1.22% 0.67% 0.53% 0.26% Supplemental data Net assets, end of period (000 s)... $345,759 $398,703 $461,596 $572,518 $624,250 $628,722 Portfolio turnover rate % 29.74% 35.77% 30.05% 21.03% 20.40% athe amount shown for a share outstanding throughout the period may not correlate with the Statement of Operations for the period due to the timing of sales and repurchases of the Fund s shares in relation to income earned and/or fluctuating fair value of the investments of the Fund. bbased on average daily shares outstanding. c Net investment income per share includes approximately $0.15 per share related to income received in the form of special dividends in connection with certain Fund holdings. Excluding this amount, the ratio of net investment income to average net assets would have been 0.91%. d Total return does not reflect sales commissions or contingent deferred sales charges, if applicable, and is not annualized for periods less than one year. eratios are annualized for periods less than one year, except for non-recurring expenses, if any. fbenefit of expense reduction rounds to less than 0.01%. g Benefit of waiver and payments by affiliates rounds to less than 0.01%. franklintempleton.com The accompanying notes are an integral part of these financial statements. Semiannual Report 23

25 FINANCIAL HIGHLIGHTS Franklin Natural Resources Fund (continued) Class C Six Months Ended October 31, 2017 (unaudited) Year Ended April 30, Per share operating performance (for a share outstanding throughout the period) Net asset value, beginning of period... $24.28 $24.25 $30.46 $38.39 $32.02 $34.96 Income from investment operations a : Net investment income (loss) b c (0.01) (0.06) (0.14) Net realized and unrealized gains (losses)... (0.35) 0.15 (6.31) (7.91) 6.43 (2.80) Total from investment operations... (0.19) 0.16 (6.20) (7.92) 6.37 (2.94) Less distributions from net investment income. (0.13) (0.01) (0.01) Net asset value, end of period... $24.09 $24.28 $24.25 $30.46 $38.39 $32.02 Total return d... (0.78)% 0.63% (20.37)% (20.63)% 19.89% (8.41)% Ratios to average net assets e Expenses before waiver and payments by affiliates % 1.81% 1.87% 1.78% 1.76% 1.77% Expenses net of waiver and payments by affiliates % f 1.80% f 1.86% 1.78% f,g 1.76% f,g 1.77% Netinvestmentincome(loss) % c 0.04% 0.49% (0.03)% (0.16)% (0.43)% Supplemental data Net assets, end of period (000 s)... $84,402 $96,835 $107,724 $123,735 $126,651 $130,424 Portfolio turnover rate % 29.74% 35.77% 30.05% 21.03% 20.40% athe amount shown for a share outstanding throughout the period may not correlate with the Statement of Operations for the period due to the timing of sales and repurchases of the Fund s shares in relation to income earned and/or fluctuating fair value of the investments of the Fund. bbased on average daily shares outstanding. c Net investment income per share includes approximately $0.15 per share related to income received in the form of special dividends in connection with certain Fund holdings. Excluding this amount, the ratio of net investment income to average net assets would have been 0.16%. d Total return does not reflect sales commissions or contingent deferred sales charges, if applicable, and is not annualized for periods less than one year. eratios are annualized for periods less than one year, except for non-recurring expenses, if any. fbenefit of expense reduction rounds to less than 0.01%. g Benefit of waiver and payments by affiliates rounds to less than 0.01%. 24 Semiannual Report The accompanying notes are an integral part of these financial statements. franklintempleton.com

26 FINANCIAL HIGHLIGHTS Franklin Natural Resources Fund (continued) Class R6 Six Months Ended October 31, 2017 (unaudited) Year Ended April 30, a Per share operating performance (for a share outstanding throughout the period) Net asset value, beginning of period... $26.87 $26.73 $33.62 $42.58 $38.28 Income from investment operations b : Net investment income c d Net realized and unrealized gains (losses)... (0.36) 0.04 (7.06) (8.92) 4.31 Total from investment operations.... (0.02) 0.51 (6.55) (8.46) 4.50 Less distributions from net investment income... (0.37) (0.34) (0.50) (0.20) Net asset value, end of period.... $26.85 $26.87 $26.73 $33.62 $42.58 Total return e... (0.07)% 1.89% (19.31)% (19.61)% 11.83% Ratios to average net assets f Expenses before waiver and payments by affiliates % 0.83% 0.60% 0.55% 0.55% Expenses net of waiver and payments by affiliates % g 0.54% g 0.55% 0.54% g 0.53% g Netinvestmentincome % d 1.30% 1.80% 1.21% 1.07% Supplemental data Net assets, end of period (000 s).... $721 $218 $15 $439 $939 Portfolio turnover rate % 29.74% 35.77% 30.05% 21.03% afor the period September 20, 2013 (effective date) to April 30, bthe amount shown for a share outstanding throughout the period may not correlate with the Statement of Operations for the period due to the timing of sales and repurchases of the Fund s shares in relation to income earned and/or fluctuating fair value of the investments of the Fund. c Based on average daily shares outstanding. d Net investment income per share includes approximately $0.15 per share related to income received in the form of special dividends in connection with certain Fund holdings. Excluding this amount, the ratio of net investment income to average net assets would have been 1.51%. etotal return is not annualized for periods less than one year. fratios are annualized for periods less than one year, except for non-recurring expenses, if any. g Benefit of expense reduction rounds to less than 0.01%. franklintempleton.com The accompanying notes are an integral part of these financial statements. Semiannual Report 25

27 FINANCIAL HIGHLIGHTS Franklin Natural Resources Fund (continued) Advisor Class Six Months Ended October 31, 2017 (unaudited) Year Ended April 30, Per share operating performance (for a share outstanding throughout the period) Net asset value, beginning of period... $26.81 $26.71 $33.63 $42.52 $35.31 $38.17 Income from investment operations a : Net investment income b c Net realized and unrealized gains (losses)... (0.39) 0.17 (7.00) (8.85) 7.10 (3.07) Total from investment operations... (0.08) 0.46 (6.64) (8.50) 7.41 (2.86) Less distributions from net investment income. (0.36) (0.28) (0.39) (0.20) Net asset value, end of period... $26.73 $26.81 $26.71 $33.63 $42.52 $35.31 Total return d... (0.30)% 1.64% (19.60)% (19.81)% 21.07% (7.49)% Ratios to average net assets e Expenses before waiver and payments by affiliates % 0.81% 0.87% 0.78% 0.77% 0.78% Expenses net of waiver and payments by affiliates % f 0.80% f 0.86% 0.78% f,g 0.77% f,g 0.78% Netinvestmentincome % c 1.04% 1.49% 0.97% 0.83% 0.56% Supplemental data Net assets, end of period (000 s)... $85,872 $94,070 $90,185 $79,307 $94,651 $117,087 Portfolio turnover rate % 29.74% 35.77% 30.05% 21.03% 20.40% athe amount shown for a share outstanding throughout the period may not correlate with the Statement of Operations for the period due to the timing of sales and repurchases of the Fund s shares in relation to income earned and/or fluctuating fair value of the investments of the Fund. bbased on average daily shares outstanding. c Net investment income per share includes approximately $0.15 per share related to income received in the form of special dividends in connection with certain Fund holdings. Excluding this amount, the ratio of net investment income to average net assets would have been 1.16%. d Total return is not annualized for periods less than one year. eratios are annualized for periods less than one year, except for non-recurring expenses, if any. fbenefit of expense reduction rounds to less than 0.01%. g Benefit of waiver and payments by affiliates rounds to less than 0.01%. 26 Semiannual Report The accompanying notes are an integral part of these financial statements. franklintempleton.com

28 Statement of Investments, October 31, 2017 (unaudited) Franklin Natural Resources Fund Country Shares Value Common Stocks 98.1% Construction Materials 0.3% acemexsabdecv,cpo,adr... Mexico 191,800 $ 1,555,498 Copper 4.1% AntofagastaPLC... UnitedKingdom 420,800 5,335,767 FirstQuantumMineralsLtd... Zambia 349,400 3,909,768 afreeport-mcmoraninc... UnitedStates 274,200 3,833,316 a ImperialMetalsCorp.... Canada 364, ,491 LundinMiningCorp.... Canada 329,900 2,517,325 SandfireResourcesNL... Australia 1,072,167 4,711,685 21,147,352 Diversified Metals & Mining 7.4% BHP Billiton PLC, ADR... UnitedKingdom 332,100 12,061,872 Glencore PLC.... Switzerland 1,843,200 8,888,414 HudbayMineralsInc... Canada 168,600 1,253,828 a NautilusMineralsInc.... Canada 3,895, ,426 anexa Resources SA... Peru 146,300 2,658,271 RioTintoPLC,ADR... UnitedKingdom 114,200 5,473,606 South32Ltd.... Australia 963,300 2,485,384 TeckResourcesLtd.,B... Canada 243,900 4,985,316 38,441,117 Gold 5.3% AgnicoEagleMinesLtd.... Canada 67,800 3,028,405 AlamosGoldInc.,A... Canada 473,500 2,999,880 ab2goldcorp... Canada 1,894,000 4,817,433 BarrickGoldCorp.... Canada 279,000 4,031,550 Goldcorp Inc.... Canada 266,800 3,484,408 aguyanagoldfieldsinc.... Canada 758,600 2,706,029 NewcrestMiningLtd... Australia 142,400 2,443,171 OceanaGoldCorp.... Australia 473,310 1,269,941 RandgoldResourcesLtd.,ADR... UnitedKingdom 5, ,658 TahoeResourcesInc... Canada 444,700 2,134,615 27,446,090 Integrated Oil & Gas 15.2% BPPLC,ADR... UnitedKingdom 127,500 5,185,425 ChevronCorp.... UnitedStates 106,500 12,342,285 ExxonMobilCorp... UnitedStates 127,000 10,585,450 OccidentalPetroleumCorp... UnitedStates 200,100 12,920,457 apetroleobrasileirosa,adr... Brazil 206,400 2,198,160 RoyalDutchShellPLC,A,ADR... UnitedKingdom 211,200 13,311,936 Suncor Energy Inc.... Canada 444,100 15,084,006 TotalSA,B,ADR... France 120,710 6,725,961 78,353,680 Oil & Gas Drilling 2.7% EnscoPLC,A... UnitedStates 346,719 1,868,815 Patterson-UTI Energy Inc.... UnitedStates 258,600 5,115,108 a PioneerEnergyServicesCorp... UnitedStates 1,898,343 3,606,852 arowancos.plc... UnitedStates 248,400 3,559,572 14,150,347 franklintempleton.com Semiannual Report 27

29 STATEMENT OF INVESTMENTS (UNAUDITED) Franklin Natural Resources Fund (continued) Country Shares Value Common Stocks (continued) Oil & Gas Equipment & Services 17.8% BakerHughesaGECo.,A... UnitedStates 155,400 $ 4,884,222 a Dril-QuipInc... UnitedStates 57,800 2,433,380 Halliburton Co.... UnitedStates 414,935 17,734,322 a HuntingPLC... UnitedKingdom 253,600 1,763,645 amammothenergyservicesinc.... UnitedStates 82,800 1,633,644 OceaneeringInternationalInc... UnitedStates 252,000 5,095,440 aoilstatesinternationalinc.... UnitedStates 183,800 4,236,590 aphiinc.,non-voting... UnitedStates 104,500 1,221,605 apropetroholdingcorp... UnitedStates 98,450 1,499,393 arangerenergyservicesinc... UnitedStates 127,400 1,477,840 RPCInc... UnitedStates 207,400 5,041,894 SchlumbergerLtd.... UnitedStates 339,847 21,750,208 a SuperiorEnergyServicesInc.... UnitedStates 1,166,800 10,291,176 a TechnipFMCPLC... UnitedKingdom 382,500 10,476,675 aweatherfordinternationalplc... UnitedStates 731,000 2,536,570 92,076,604 Oil & Gas Exploration & Production 34.6% AnadarkoPetroleumCorp... UnitedStates 373,300 18,429,821 CabotOil&GasCorp.,A... UnitedStates 464,500 12,866,650 a CairnEnergyPLC... UnitedKingdom 1,903,100 5,344,558 a CallonPetroleumCo... UnitedStates 507,200 5,624,848 Canadian Natural Resources Ltd.... Canada 297,800 10,396,616 a ConchoResourcesInc... UnitedStates 107,900 14,481,259 ConocoPhillips... UnitedStates 287,200 14,690,280 a DiamondbackEnergyInc... UnitedStates 93,400 10,008,744 EOGResourcesInc... UnitedStates 182,400 18,216,288 EQTCorp... UnitedStates 164,900 10,312,846 HessCorp... UnitedStates 215,500 9,516,480 a JaggedPeakEnergyInc... UnitedStates 492,300 6,838,047 a Matador Resources Co.... UnitedStates 197,346 5,239,536 NobleEnergyInc... UnitedStates 562,100 15,665,727 PioneerNaturalResourcesCo... UnitedStates 87,300 13,066,191 aresolute Energy Corp.... UnitedStates 178,300 5,354,349 a SanchezEnergyCorp... UnitedStates 22,916 99,226 a SRCEnergyInc... UnitedStates 282,900 2,698, ,850,332 Oil & Gas Refining & Marketing 4.3% HollyFrontierCorp.... UnitedStates 147,800 5,461,210 MarathonPetroleumCorp... UnitedStates 92,400 5,519,976 Phillips UnitedStates 60,500 5,510,340 ValeroEnergyCorp... UnitedStates 69,700 5,498,633 21,990,159 Oil & Gas Storage & Transportation 5.4% EnbridgeInc... Canada 216,147 8,313,014 KinderMorganInc... UnitedStates 723,400 13,100,774 TargaResourcesCorp... UnitedStates 156,500 6,494,750 27,908, Semiannual Report franklintempleton.com

30 STATEMENT OF INVESTMENTS (UNAUDITED) Franklin Natural Resources Fund (continued) Country Shares Value Common Stocks (continued) Specialty Chemicals 0.6% AlbemarleCorp... UnitedStates 9,700 $ 1,366,633 UmicoreSA... Belgium 32,200 1,439,436 2,806,069 Trading Companies & Distributors 0.4% a UnivarInc... UnitedStates 64,300 1,912,925 Total Common Stocks (Cost $434,206,105) ,638,711 Convertible Preferred Stocks 1.0% Oil & Gas Exploration & Production 1.0% HessCorp.,8.00%,cvt.pfd... UnitedStates 52,900 2,920,080 SanchezEnergyCorp.,4.875%,cvt.pfd.,A... UnitedStates 84,500 1,378,406 SanchezEnergyCorp.,6.50%,cvt.pfd.,B... UnitedStates 56,000 1,032,080 Total Convertible Preferred Stocks (Cost $9,744,127)... 5,330,566 Principal Amount Convertible Bonds (Cost $3,695,183) 0.1% Oil & Gas Exploration & Production 0.1% CobaltInternationalEnergyInc.,cvt.,seniorbond,3.125%,5/15/24... UnitedStates$4,787, ,245 Total Investments before Short Term Investments (Cost $447,645,415) ,615,522 Short Term Investments (Cost $3,576,752) 0.7% Money Market Funds 0.7% Shares b,c InstitutionalFiduciaryTrustMoneyMarketPortfolio,0.69%... UnitedStates 3,576,752 3,576,752 Total Investments (Cost $451,222,167) 99.9% ,192,274 Other Assets, less Liabilities 0.1% ,013 Net Assets 100.0%... $516,754,287 See Abbreviations on page 45. a Non-income producing. bsee Note 3(f) regarding investments in affiliated management investment companies. cthe rate shown is the annualized seven-day yield at period end. franklintempleton.com The accompanying notes are an integral part of these financial statements. Semiannual Report 29

31 Financial Statements Statements of Assets and Liabilities October 31, 2017 (unaudited) Franklin Biotechnology Discovery Fund Franklin Natural Resources Fund Assets: Investments in securities: Cost - Unaffiliated issuers... $ 839,480,581 $ 447,645,415 Cost - Non-controlled affiliates (Note 3f and 9)... 88,329,225 3,576,752 Value - Unaffiliated issuers... $1,366,409,055 $ 512,615,522 Value - Non-controlled affiliates (Note 3f and 9)... 87,226,337 3,576,752 Receivables: Investment securities sold... 2,390,214 Capital shares sold... 1,729, ,315 Dividendsandinterest , ,020 Duefromcustodian ,000 Other assets Total assets... 1,455,700, ,526,023 Liabilities: Payables: Investment securities purchased , ,138 Capital shares redeemed... 1,817,543 1,010,721 Managementfees , ,844 Distributionfees , ,749 Transferagentfees , ,478 Payableuponreturnofsecuritiesloaned... 49,012,987 Accrued expenses and other liabilities ,256 67,806 Total liabilities... 53,423,509 2,771,736 Net assets, at value... $1,402,276,554 $ 516,754,287 Net assets consist of: Paid-incapital... $ 847,055,103 $626,100,149 Undistributednetinvestmentincome(loss)... (9,129,010) 7,198,917 Netunrealizedappreciation(depreciation) ,825,586 64,963,161 Accumulatednetrealizedgain(loss)... 38,524,875 (181,507,940) Net assets, at value... $1,402,276,554 $ 516,754,287 +Includes securities loaned... $ 47,185,993 $ 30 Semiannual Report The accompanying notes are an integral part of these financial statements. franklintempleton.com

32 FINANCIAL STATEMENTS Statements of Assets and Liabilities (continued) October 31, 2017 (unaudited) Franklin Biotechnology Discovery Fund Franklin Natural Resources Fund Class A: Net assets, at value... $1,153,401,345 $345,759,071 Sharesoutstanding... 7,668,840 13,826,523 Net asset value per share a... $ $25.01 Maximum offering price per share (net asset value per share 94.25%)... $ $26.54 Class C: Net assets, at value... $ 57,333,561 $ 84,401,861 Sharesoutstanding ,286 3,504,120 Net asset value and maximum offering price per share a... $ $24.09 Class R6: Net assets, at value... $ 8,871,794 $ 721,428 Sharesoutstanding... 57,366 26,872 Net asset value and maximum offering price per share... $ $26.85 Advisor Class: Net assets, at value... $ 182,669,854 $ 85,871,927 Sharesoutstanding... 1,188,965 3,212,323 Net asset value and maximum offering price per share... $ $26.73 aredemption price is equal to net asset value less contingent deferred sales charges, if applicable. franklintempleton.com The accompanying notes are an integral part of these financial statements. Semiannual Report 31

33 FINANCIAL STATEMENTS Statements of Operations for the six months ended October 31, 2017 (unaudited) Franklin Biotechnology Discovery Fund Franklin Natural Resources Fund Investment income: Dividends: Unaffiliated issuers... $ 2,951,773 $ 8,712,320 Non-controlled affiliates (Note 3f and 9)... 92,765 13,973 Interest: Unaffiliated issuers ,039 Income from securities loaned (net of fees and rebates)... 1,597,327 28,778 Totalinvestmentincome... 4,641,865 8,893,110 Expenses: Managementfees(Note3a)... 4,190,633 1,333,937 Distribution fees: (Note 3c) ClassA... 1,492, ,344 ClassC , ,347 Transfer agent fees: (Note 3e) ClassA... 1,332, ,175 ClassC... 64, ,717 ClassR AdvisorClass , ,747 Custodianfees(Note4)... 6,576 6,748 Reports to shareholders... 77,041 73,408 Registration and filing fees... 54,317 41,674 Professional fees... 34,298 21,550 Trustees feesandexpenses... 6,790 3,355 Other... 14,547 8,960 Total expenses.... 7,760,648 3,512,323 Expensereductions(Note4)... (151) (225) Expenses waived/paid by affiliates (Note 3f and 3g)... (158,337) (13,364) Netexpenses... 7,602,160 3,498,734 Net investment income (loss)... (2,960,295) 5,394,376 Realized and unrealized gains (losses): Net realized gain (loss) from: Investments: Unaffiliated issuers... 11,944,670 (22,022,340) Foreigncurrencytransactions... (721) 20,568 Netrealizedgain(loss)... 11,943,949 (22,001,772) Net change in unrealized appreciation (depreciation) on: Investments: Unaffiliated issuers... 18,783,201 11,360,107 Non-controlled affiliates (Note 3f and 9).... 1,156,948 Translation of other assets and liabilities denominatedinforeigncurrencies ,698 (8,723) Netchangeinunrealizedappreciation(depreciation)... 20,195,847 11,351,384 Netrealizedandunrealizedgain(loss)... 32,139,796 (10,650,388) Netincrease(decrease)innetassetsresultingfromoperations... $29,179,501 $ (5,256,012) 32 Semiannual Report The accompanying notes are an integral part of these financial statements. franklintempleton.com

34 FINANCIAL STATEMENTS Statements of Changes in Net Assets Franklin Biotechnology Discovery Fund Six Months Ended October 31, 2017 (unaudited) Year Ended April 30, 2017 Franklin Natural Resources Fund Six Months Ended October 31, 2017 (unaudited) Year Ended April 30, 2017 Increase (decrease) in net assets: Operations: Netinvestmentincome(loss)... $ (2,960,295) $ (7,464,858) $ 5,394,376 $ 4,573,924 Netrealizedgain(loss)... 11,943,949 98,018,256 (22,001,772) (16,276,712) Net change in unrealized appreciation (depreciation)... 20,195, ,090,624 11,351,384 23,243,049 Net increase (decrease) in net assets resulting from operations... 29,179, ,644,022 (5,256,012) 11,540,261 Distributions to shareholders from: Net investment income: ClassA... (14,076,436) (4,756,117) ClassC... (408,909) (577,641) ClassR6... (126,292) (212) AdvisorClass... (1,688,739) (1,234,610) Net realized gains: ClassA... (34,234,146) ClassC... (1,330,584) ClassR6... (230,582) AdvisorClass... (3,411,647) Totaldistributionstoshareholders... (55,507,335) (6,568,580) Capital share transactions: (Note 2) ClassA... (47,548,229) (55,488,311) (49,442,552) (66,989,230) ClassC... 2,438,917 31,398,641 (11,311,029) (11,600,701) ClassR6... (178,909) 2,002, , ,601 AdvisorClass... 18,978,022 50,061,306 (7,563,225) 3,702,378 Total capital share transactions.... (26,310,199) 27,974,327 (67,815,626) (74,664,952) Net increase (decrease) in net assets... 2,869, ,111,014 (73,071,638) (69,693,271) Net assets: Beginningofperiod... 1,399,407,252 1,191,296, ,825, ,519,196 Endofperiod... $1,402,276,554 $1,399,407,252 $516,754,287 $589,825,925 Undistributed net investment income (loss) included in net assets: Endofperiod... $ (9,129,010) $ $ 7,198,917 $ 1,804,541 Distributions in excess of net investment income included in net assets: Endofperiod... $ $ (6,168,715) $ $ franklintempleton.com The accompanying notes are an integral part of these financial statements. Semiannual Report 33

35 Notes to Financial Statements (unaudited) 1. Organization and Significant Accounting Policies Franklin Strategic Series (Trust) is registered under the Investment Company Act of 1940 (1940 Act) as an open-end management investment company, consisting of eight separate funds, two of which are included in this report (Funds) and applies the specialized accounting and reporting guidance in U.S. Generally Accepted Accounting Principles (U.S. GAAP). The Funds offer four classes of shares: Class A, Class C, Class R6, and Advisor Class. Each class of shares may differ by its initial sales load, contingent deferred sales charges, voting rights on matters affecting a single class, its exchange privilege and fees due to differing arrangements for distribution and transfer agent fees. The following summarizes the Funds significant accounting policies. a. Financial Instrument Valuation The Funds investments in financial instruments are carried at fair value daily. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. The Funds calculate the net asset value (NAV) per share as of 4 p.m. Eastern time each day the New York Stock Exchange (NYSE) is open for trading. Under compliance policies and procedures approved by the Trust s Board of Trustees (the Board), the Funds administrator has responsibility for oversight of valuation, including leading the cross-functional Valuation Committee (VC). The VC provides administration and oversight of the Funds valuation policies and procedures, which are approved annually by the Board. Among other things, these procedures allow the Funds to utilize independent pricing services, quotations from securities and financial instrument dealers, and other market sources to determine fair value. Equity securities listed on an exchange or on the NASDAQ National Market System are valued at the last quoted sale price or the official closing price of the day, respectively. Foreign equity securities are valued as of the close of trading on the foreign stock exchange on which the security is primarily traded, or as of 4 p.m. Eastern time. The value is then converted into its U.S. dollar equivalent at the foreign exchange rate in effect at 4 p.m. Eastern time on the day that the value of the security is determined. Over-the-counter (OTC) securities are valued within the range of the most recent quoted bid and ask prices. Securities that trade in multiple markets or on multiple exchanges are valued according to the broadest and most representative market. Certain equity securities are valued based upon fundamental characteristics or relationships to similar securities. Debt securities generally trade in the OTC market rather than on a securities exchange. The Funds pricing services use multiple valuation techniques to determine fair value. In instances where sufficient market activity exists, the pricing services may utilize a market-based approach through which quotes from market makers are used to determine fair value. In instances where sufficient market activity may not exist or is limited, the pricing services also utilize proprietary valuation models which may consider market characteristics such as benchmark yield curves, credit spreads, estimated default rates, anticipated market interest rate volatility, coupon rates, anticipated timing of principal repayments, underlying collateral, and other unique security features in order to estimate the relevant cash flows, which are then discounted to calculate the fair value. Investments in open-end mutual funds are valued at the closing NAV. The Funds have procedures to determine the fair value of financial instruments for which market prices are not reliable or readily available. Under these procedures, the VC convenes on a regular basis to review such financial instruments and considers a number of factors, including significant unobservable valuation inputs, when arriving at fair value. The VC primarily employs a market-based approach which may use related or comparable assets or liabilities, recent transactions, market multiples, book values, and other relevant information for the investment to determine the fair value of the investment. An income-based valuation approach may also be used in which the anticipated future cash flows of the investment are discounted to calculate fair value. Discounts may also be applied due to the nature or duration of any restrictions on the disposition of the investments. Due to the inherent uncertainty of valuations of such investments, the fair values may differ significantly from the values that would have been used had an active market existed. The VC employs various methods for calibrating these valuation approaches including a regular review of key inputs and assumptions, transactional back-testing or disposition analysis, and reviews of any related market activity. 34 Semiannual Report franklintempleton.com

36 NOTES TO FINANCIAL STATEMENTS (UNAUDITED) Trading in securities on foreign securities stock exchanges and OTC markets may be completed before 4 p.m. Eastern time. In addition, trading in certain foreign markets may not take place on every Funds business day. Occasionally, events occur between the time at which trading in a foreign security is completed and 4 p.m. Eastern time that might call into question the reliability of the value of a portfolio security held by the Fund. As a result, differences may arise between the value of the Funds portfolio securities as determined at the foreign market close and the latest indications of value at 4 p.m. Eastern time. In order to minimize the potential for these differences, the VC monitors price movements following the close of trading in foreign stock markets through a series of country specific market proxies (such as baskets of American Depositary Receipts, futures contracts and exchange traded funds). These price movements are measured against established trigger thresholds for each specific market proxy to assist in determining if an event has occurred that may call into question the reliability of the values of the foreign securities held by the Funds. If such an event occurs, the securities may be valued using fair value procedures, which may include the use of independent pricing services. When the last day of the reporting period is a non-business day, certain foreign markets may be open on those days that the Funds NAV is not calculated, which could result in differences between the value of the Funds portfolio securities on the last business day and the last calendar day of the reporting period. Any significant security valuation changes due to an open foreign market are adjusted and reflected by the Funds for financial reporting purposes. b. Foreign Currency Translation Portfolio securities and other assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the exchange rate of such currencies against U.S. dollars on the date of valuation. The Funds may enter into foreign currency exchange contracts to facilitate transactions denominated in a foreign currency. Purchases and sales of securities, income and expense items denominated in foreign currencies are translated into U.S. dollars at the exchange rate in effect on the transaction date. Portfolio securities and assets and liabilities denominated in foreign currencies contain risks that those currencies will decline in value relative to the U.S. dollar. Occasionally, events may impact the availability or reliability of foreign exchange rates used to convert the U.S. dollar equivalent value. If such an event occurs, the foreign exchange rate will be valued at fair value using procedures established and approved by the Board. The Funds do not separately report the effect of changes in foreign exchange rates from changes in market prices on securities held. Such changes are included in net realized and unrealized gain or loss from investments in the Statements of Operations. Realized foreign exchange gains or losses arise from sales of foreign currencies, currency gains or losses realized between the trade and settlement dates on securities transactions and the difference between the recorded amounts of dividends, interest, and foreign withholding taxes and the U.S. dollar equivalent of the amounts actually received or paid. Net unrealized foreign exchange gains and losses arise from changes in foreign exchange rates on foreign denominated assets and liabilities other than investments in securities held at the end of the reporting period. c. Securities Lending Certain or all Funds participate in an agency based securities lending program to earn additional income. The Fund receives cash collateral against the loaned securities in an amount equal to at least 102% of the fair value of the loaned securities. Collateral is maintained over the life of the loan in an amount not less than 100% of the fair value of loaned securities, as determined at the close of Fund business each day; any additional collateral required due to changes in security values is delivered to the Fund on the next business day. The collateral is deposited into a joint cash account with other funds and is used to invest in a money market fund managed by Franklin Advisers, Inc., an affiliate of the Funds, and/or uninvested cash as included in due from custodian in the Statements of Assets and Liabilities. The Fund may receive income from the investment of cash collateral, in addition to lending fees and rebates paid by the borrower. Income from securities loaned, net of fees paid to the securities lending agent and/or third-party vendor, is reported separately in the Statements of Operations. The Fund bears the market risk with respect to the collateral investment, securities loaned, and the risk that the agent may default on its obligations to the Fund. If the borrower defaults on its obligation to return the securities loaned, the Fund has the franklintempleton.com Semiannual Report 35

37 NOTES TO FINANCIAL STATEMENTS (UNAUDITED) 1. Organization and Significant Accounting Policies (continued) c. Securities Lending (continued) right to repurchase the securities in the open market using the collateral received. The securities lending agent has agreed to indemnify the Fund in the event of default by a third party borrower. d. Income and Deferred Taxes It is each Fund s policy to qualify as a regulated investment company under the Internal Revenue Code. Each Fund intends to distribute to shareholders substantially all of its taxable income and net realized gains to relieve it from federal income and excise taxes. As a result, no provision for U.S. federal income taxes is required. The Funds may be subject to foreign taxation related to income received, capital gains on the sale of securities and certain foreign currency transactions in the foreign jurisdictions in which the Funds invest. Foreign taxes, if any, are recorded based on the tax regulations and rates that exist in the foreign markets in which the Funds invest. When a capital gain tax is determined to apply, certain or all Funds record an estimated deferred tax liability in an amount that would be payable if the securities were disposed of on the valuation date. Each Fund may recognize an income tax liability related to its uncertain tax positions under U.S. GAAP when the uncertain tax position has a less than 50% probability that it will be sustained upon examination by the tax authorities based on its technical merits. As of October 31, 2017, each Fund has determined that no tax liability is required in its financial statements related to uncertain tax positions for any open tax years (or expected to be taken in future tax years). Open tax years are those that remain subject to examination and are based on the statute of limitations in each jurisdiction in which the Fund invests. e. Security Transactions, Investment Income, Expenses and Distributions Security transactions are accounted for on trade date. Realized gains and losses on security transactions are determined on a specific identification basis. Interest income and estimated expenses are accrued daily. Dividend income is recorded on the ex-dividend date except for certain dividends from securities where the dividend rate is not available. In such cases, the dividend is recorded as soon as the information is received by the Funds. Distributions to shareholders are recorded on the ex-dividend date. Distributable earnings are determined according to income tax regulations (tax basis) and may differ from earnings recorded in accordance with U.S. GAAP. These differences may be permanent or temporary. Permanent differences are reclassified among capital accounts to reflect their tax character. These reclassifications have no impact on net assets or the results of operations. Temporary differences are not reclassified, as they may reverse in subsequent periods. Common expenses incurred by the Trust are allocated among the Funds based on the ratio of net assets of each Fund to the combined net assets of the Trust. Fund specific expenses are charged directly to the Fund that incurred the expense. Realized and unrealized gains and losses and net investment income, excluding class specific expenses, are allocated daily to each class of shares based upon the relative proportion of net assets of each class. Differences in per share distributions by class are generally due to differences in class specific expenses. f. Accounting Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the amounts of income and expenses during the reporting period. Actual results could differ from those estimates. g. Guarantees and Indemnifications Under the Trust s organizational documents, its officers and trustees are indemnified by the Trust against certain liabilities arising out of the performance of their duties to the Trust. Additionally, in the normal course of business, the Trust, on behalf of the Funds, enters into contracts with service providers that contain general indemnification clauses. The Trust s maximum exposure under these arrangements is unknown as this would involve future claims that may be made against the Trust that have not yet occurred. Currently, the Trust expects the risk of loss to be remote. 36 Semiannual Report franklintempleton.com

38 NOTES TO FINANCIAL STATEMENTS (UNAUDITED) 2. Shares of Beneficial Interest At October 31, 2017, there were an unlimited number of shares authorized (without par value). Transactions in the Funds shares were as follows: Franklin Biotechnology Discovery Fund Franklin Natural Resources Fund Shares Amount Shares Amount Class A Shares: Six Months ended October 31, 2017 Sharessold ,501 $ 87,656, ,412 $ 20,106,697 Sharesredeemed... (899,105) (135,204,260) (2,881,078) (69,549,249) Netincrease(decrease)... (323,604) $ (47,548,229) (2,050,666) $ (49,442,552) Year ended April 30, 2017 Sharessold... 2,141,244 $293,440,540 3,407,729 $ 87,917,703 Shares issued in reinvestment of distributions ,251 45,878, ,961 4,629,546 Sharesredeemed... (2,881,393) (394,807,631) (6,146,306) (159,536,479) Netincrease(decrease)... (392,898) $ (55,488,311) (2,569,616) $ (66,989,230) Class C Shares: Six Months ended October 31, 2017 Sharessold... 74,216 $ 11,003, ,238 $ 5,319,625 Sharesredeemed... (57,547) (8,564,544) (712,605) (16,630,654) Netincrease(decrease)... 16,669 $ 2,438,917 (484,367) $ (11,311,029) Year ended April 30, 2017 Sharessold ,992 $ 42,287, ,399 $ 19,979,661 Shares issued in reinvestment of distributions ,374 1,732,743 21, ,336 Sharesredeemed... (93,143) (12,622,045) (1,275,577) (32,138,698) Netincrease(decrease) ,223 $ 31,398,641 (453,156) $ (11,600,701) ClassR6Shares: Six Months ended October 31, 2017 Sharessold... 7,928 $ 1,235,782 19,957 $ 532,956 Sharesredeemed... (9,428) (1,414,691) (1,201) (31,776) Netincrease(decrease)... (1,500) $ (178,909) 18,756 $ 501,180 Year ended April 30, 2017 Sharessold... 38,854 $ 5,153,854 7,779 $ 228,431 Shares issued in reinvestment of distributions.... 2, , Sharesredeemed... (25,011) (3,508,037) (222) (6,041) Netincrease(decrease)... 16,480 $ 2,002,691 7,564 $ 222,601 Advisor Class Shares: Six Months ended October 31, 2017 Sharessold ,372 $ 41,961, ,649 $ 16,663,010 Sharesredeemed... (149,939) (22,983,062) (941,122) (24,226,235) Netincrease(decrease) ,433 $ 18,978,022 (296,473) $ (7,563,225) Year ended April 30, 2017 Sharessold ,833 $ 93,724,820 1,645,341 $ 45,812,950 Shares issued in reinvestment of distributions ,641 4,260,757 40,400 1,180,483 Sharesredeemed... (343,647) (47,924,271) (1,553,855) (43,291,055) Netincrease(decrease) ,827 $ 50,061, ,886 $ 3,702,378 franklintempleton.com Semiannual Report 37

39 NOTES TO FINANCIAL STATEMENTS (UNAUDITED) 3. Transactions with Affiliates Franklin Resources, Inc. is the holding company for various subsidiaries that together are referred to as Franklin Templeton Investments. Certain officers and trustees of the Trust are also officers and/or directors of the following subsidiaries: Subsidiary Franklin Advisers, Inc. (Advisers) Franklin Templeton Services, LLC (FT Services) Franklin Templeton Distributors, Inc. (Distributors) Franklin Templeton Investor Services, LLC (Investor Services) Affiliation Investment manager Administrative manager Principal underwriter Transfer agent a. Management Fees Franklin Biotechnology Discovery Fund pays an investment management fee to Advisers based on the average daily net assets of the Fund as follows: Annualized Fee Rate Net Assets 0.775% Up to and including $100 million 0.650% Over $100 million, up to and including $200 million 0.635% Over $200 million, up to and including $250 million 0.585% Over $250 million, up to and including $700 million 0.550% Over $700 million, up to and including $1.2 billion 0.525% Over $1.2 billion, up to and including $7.5 billion 0.515% Over $7.5 billion, up to and including $10 billion 0.505% Over $10 billion, up to and including $12.5 billion 0.495% Over $12.5 billion, up to and including $15 billion 0.475% in excess of $15 billion Franklin Natural Resources Fund pays an investment management fee to Advisers based on the average daily net assets of the Fund as follows: Annualized Fee Rate Net Assets 0.625% Up to and including $100 million 0.500% Over $100 million, up to and including $250 million 0.450% Over $250 million, up to and including $7.5 billion 0.440% Over $7.5 billion, up to and including $10 billion 0.430% Over $10 billion, up to and including $12.5 billion 0.420% Over $12.5 billion, up to and including $15 billion 0.400% In excess of $15 billion For the period ended October 31, 2017, each Fund s annualized effective investment management fee rate based on average daily net assets was as follows: Franklin Biotechnology Discovery Fund Franklin Natural Resources Fund 0.583% 0.497% 38 Semiannual Report franklintempleton.com

40 NOTES TO FINANCIAL STATEMENTS (UNAUDITED) b. Administrative Fees Under an agreement with Advisers, FT Services provides administrative services to the Funds. The fee is paid by Advisers based on the Funds average daily net assets, and is not an additional expense of the Funds. c. Distribution Fees The Board has adopted distribution plans for each share class, with the exception of Class R6 and Advisor Class shares, pursuant to Rule 12b-1 under the 1940 Act. Under the Funds Class A reimbursement distribution plans, the Funds reimburse Distributors for costs incurred in connection with the servicing, sale and distribution of each Fund s shares up to the maximum annual plan rate for each class. Under the Class A reimbursement distribution plans, costs exceeding the maximum for the current plan year cannot be reimbursed in subsequent periods. In addition, under the Funds Class C compensation distribution plans, the Funds pays Distributors for costs incurred in connection with the servicing, sale and distribution of each Fund s shares up to the maximum annual plan rate for each class. The plan year, for purposes of monitoring compliance with the maximum annual plan rates, is February 1 through January 31 for each Fund. The maximum annual plan rates, based on the average daily net assets, for each class, are as follows: ClassA % ClassC % The Board has set the current rate at 0.25% per year for Class A shares until further notice and approval by the Board. d. Sales Charges/Underwriting Agreements Front-end sales charges and contingent deferred sales charges (CDSC) do not represent expenses of the Funds. These charges are deducted from the proceeds of sales of fund shares prior to investment or from redemption proceeds prior to remittance, as applicable. Distributors has advised the Funds of the following commission transactions related to the sales and redemptions of the Funds shares for the period: Franklin Biotechnology Discovery Fund Franklin Natural Resources Fund Sales charges retained net of commissions paid to unaffiliated brokers/dealers... $205,313 $35,061 CDSC retained... $ 9,394 $ 6,341 e. Transfer Agent Fees Each class of shares, except for Class R6 pays transfer agent fees to Investor Services for its performance of shareholder servicing obligations and reimburses Investor Services for out of pocket expenses incurred, including shareholder servicing fees paid to third parties. These fees are allocated daily based upon their relative proportion of such classes aggregate net assets. Class R6 pays Investor Services transfer agent fees specific to that class. For the period ended October 31, 2017, the Funds paid transfer agent fees as noted in the Statements of Operations of which the following amounts were retained by Investor Services: Franklin Biotechnology Discovery Fund Franklin Natural Resources Fund Transferagentfees... $486,317 $356,002 franklintempleton.com Semiannual Report 39

41 NOTES TO FINANCIAL STATEMENTS (UNAUDITED) 3. Transactions with Affiliates (continued) f. Investments in Affiliated Management Investment Companies Certain or all Funds invest in one or more affiliated management investment companies for purposes other than exercising a controlling influence over the management or policies. Management fees paid by the Funds are waived on assets invested in the affiliated management investment companies, as noted in the Statements of Operations, in an amount not to exceed the management and administrative fees paid directly or indirectly by each affiliate. Prior to May 1, 2013, the waiver was accounted for as a reduction to management fees. During the period ended October 31, 2017, investments in affiliated management investment companies were as follows: Number of Shares Held at Beginning of Period Gross Additions Gross Reductions Number of Shares Held at End of Period Value at End of Period Dividend Income Net Change in Unrealized Realized Appreciation Gain (Loss) (Depreciation) Franklin Biotechnology Discovery Fund Non-Controlled Affiliates Institutional Fiduciary Trust Money Market Portfolio, 0.69% ,673, ,451,108 (333,948,399) 73,175,851 $73,175,851 $92,765 $ $ Franklin Natural Resources Fund Non-Controlled Affiliates Institutional Fiduciary Trust Money Market Portfolio, 0.69%.... 7,627,816 77,337,891 (81,388,955) 3,576,752 $ 3,576,752 $13,973 $ $ g. Waiver and Expense Reimbursements For Franklin Biotechnology Discovery Fund, Investor Services has voluntarily agreed in advance to waive or limit its fees so that the Class R6 transfer agent fees do not exceed 0.01%. For Franklin Natural Resources Fund, Investor Services has contractually agreed in advance to waive or limit its fees so that the Class R6 transfer agent fees do not exceed 0.03% until August 31, Investor Services may discontinue this waiver in the future. h. Interfund Transactions Franklin Biotechnology Discovery Fund engaged in purchases and sales of investments with funds or other accounts that have common investment managers (or affiliated investment managers), directors, trustees or officers. During the period ended October 31, 2017, these purchase and sale transactions aggregated $1,236,222 and $0, respectively. 4. Expense Offset Arrangement The Funds have entered into an arrangement with their custodian whereby credits realized as a result of uninvested cash balances are used to reduce a portion of the Funds custodian expenses. During the period ended October 31, 2017, the custodian fees were reduced as noted in the Statements of Operations. 5. Income Taxes For tax purposes, capital losses may be carried over to offset future capital gains. Capital loss carryforwards with no expiration, if any, must be fully utilized before those losses with expiration dates. 40 Semiannual Report franklintempleton.com

42 NOTES TO FINANCIAL STATEMENTS (UNAUDITED) At April 30, 2017, the capital loss carryforwards were as follows: Franklin Natural Resources Fund Capital loss carryforwards subject to expiration: ,737,677 Capital loss carryforwards not subject to expiration: Shortterm... 10,125,851 Longterm... 21,740,159 Totalcapitallosscarryforwards... 44,603,687 At October 31, 2017, the cost of investments and net unrealized appreciation (depreciation) for income tax purposes were as follows: Franklin Biotechnology Discovery Fund Franklin Natural Resources Fund Costofinvestments... $937,827,135 $468,620,877 Unrealizedappreciation... $608,674,289 $111,324,759 Unrealizeddepreciation... (92,866,032) (63,753,362) Netunrealizedappreciation(depreciation)... $515,808,257 $ 47,571,397 Differences between income and/or capital gains as determined on a book basis and a tax basis are primarily due to differing treatments of passive foreign investment company shares and wash sales. 6. Investment Transactions Purchases and sales of investments (excluding short term securities) for the period ended October 31, 2017, were as follows: Franklin Biotechnology Discovery Fund Franklin Natural Resources Fund Purchases... $169,281,482 $ 78,850,409 Sales... $189,641,619 $136,880,783 At October 31, 2017, in connection with securities lending transactions, certain or all Funds loaned investments and received cash collateral as follows: Franklin Biotechnology Discovery Fund Securities lending transactions a : Equity Investments b... $49,012,987 athe agreements can be terminated at any time. bthe gross amount of recognized liability for such transactions is included in payable upon return of securities loaned in the Statements of Assets and Liabilities. 7. Concentration of Risk Investing in foreign securities may include certain risks and considerations not typically associated with investing in U.S. securities, such as fluctuating currency values and changing local and regional economic, political and social conditions, which may result in greater market volatility. In addition, certain foreign securities may not be as liquid as U.S. securities. franklintempleton.com Semiannual Report 41

43 NOTES TO FINANCIAL STATEMENTS (UNAUDITED) 8. Restricted Securities Certain or all Funds invest in securities that are restricted under the Securities Act of 1933 (1933 Act). Restricted securities are often purchased in private placement transactions, and cannot be sold without prior registration unless the sale is pursuant to an exemption under the 1933 Act. Disposal of these securities may require greater effort and expense, and prompt sale at an acceptable price may be difficult. The Funds may have registration rights for restricted securities. The issuer generally incurs all registration costs. At October 31, 2017, investments in restricted securities, excluding securities exempt from registration under the 1933 Act deemed to be liquid, were as follows: Shares Issuer Acquisition Date Cost Value Franklin Biotechnology Discovery Fund 314,126 G1TherapeuticsInc.,PrivatePlacement... 4/26/16 $2,799,999 $ 7,267,468 80,195 IntarciaTherapeuticsInc.,DD... 3/26/14 2,597,516 3,484,900 93,991 OdonateTherapeuticsLLC,RegD... 9/01/17 2,799,992 2,799,992 Total Restricted Securities (Valueis1.0%ofNetAssets)... $8,197,507 $13,552, Holdings of 5% Voting Securities of Portfolio Companies The 1940 Act defines "affiliated companies" to include investments in portfolio companies in which a fund owns 5% or more of the outstanding voting securities. During the period ended October 31, 2017, investments in affiliated companies were as follows: Name of Issuer Number of Shares/ Warrants Held at Beginning of Period Gross Additions Gross Reductions Number of Shares/ Warrants Held at End of Period Value at End of Period Dividend Income Realized Gain (Loss) Net Change in Unrealized Appreciation (Depreciation) Franklin Biotechnology Discovery Fund Non-Controlled Affiliates Alcobra Ltd ,737,306 1,737,306 $ 2,727,570 $ $ $ 729,668 ARCA biopharma Inc , ,077 a a ARCA biopharma Inc., wts., 6/16/ ,338,619 1,338,619 a a BioPharmX Corp.... 1,900,375 91,200 1,991,575 a a BioPharmX Corp., 144A.... 1,945,737 1,945,737 a a BioPharmX Corp., wts., 3/29/ , ,000 a a BioPharmX Corp., wts., 11/22/ ,259, ,975 1,679,900 a a Fate Therapeutics Inc ,373,777 2,373,777 11,322, ,280 Total Affiliated Securities (Value is 1.0% of Net Assets).... $14,050,486 $ $ $1,156,948 aas of October 31, 2017, no longer an affiliate. 10. Credit Facility The Funds, together with other U.S. registered and foreign investment funds (collectively, Borrowers), managed by Franklin Templeton Investments, are borrowers in a joint syndicated senior unsecured credit facility totaling $2 billion (Global Credit Facility) which matures on February 9, This Global Credit Facility provides a source of funds to the Borrowers for temporary and emergency purposes, including the ability to meet future unanticipated or unusually large redemption requests. 42 Semiannual Report franklintempleton.com

44 NOTES TO FINANCIAL STATEMENTS (UNAUDITED) Under the terms of the Global Credit Facility, the Funds shall, in addition to interest charged on any borrowings made by the Funds and other costs incurred by the Funds, pay their share of fees and expenses incurred in connection with the implementation and maintenance of the Global Credit Facility, based upon their relative share of the aggregate net assets of all of the Borrowers, including an annual commitment fee of 0.15% based upon the unused portion of the Global Credit Facility. These fees are reflected in other expenses in the Statements of Operations. During the period ended October 31, 2017, the Funds did not use the Global Credit Facility. 11. Fair Value Measurements The Funds follow a fair value hierarchy that distinguishes between market data obtained from independent sources (observable inputs) and the Funds own market assumptions (unobservable inputs). These inputs are used in determining the value of the Funds financial instruments and are summarized in the following fair value hierarchy: Level 1 quoted prices in active markets for identical financial instruments Level 2 other significant observable inputs (including quoted prices for similar financial instruments, interest rates, prepayment speed, credit risk, etc.) Level 3 significant unobservable inputs (including the Funds own assumptions in determining the fair value of financial instruments) The input levels are not necessarily an indication of the risk or liquidity associated with financial instruments at that level. For movements between the levels within the fair value hierarchy, the Funds have adopted a policy of recognizing the transfers as of the date of the underlying event which caused the movement. A summary of inputs used as of October 31, 2017, in valuing the Funds assets carried at fair value, is as follows: Level 1 Level 2 Level 3 Total Franklin Biotechnology Discovery Fund Assets: Investments in Securities: Equity Investments: a Biotechnology... $ 1,167,153,110 $ b $ 13,613,815 $ 1,180,766,925 Pharmaceuticals ,479, , ,603,012 All Other Equity Investments c... 65,742,876 65,742,876 EscrowsandLitigationTrusts... 1,346,728 1,346,728 ShortTermInvestments... 73,175,851 73,175,851 TotalInvestmentsinSecurities... $ 1,438,551,114 $ $ 15,084,278 $ 1,453,635,392 Franklin Natural Resources Fund Assets: Investments in Securities: Equity Investments: a Oil & Gas Exploration & Production... $ 181,770,412 $ 2,410,486 $ $ 184,180,898 All Other Equity Investments c ,788, ,788,379 Convertible Bonds , ,245 ShortTermInvestments... 3,576,752 3,576,752 TotalInvestmentsinSecurities... $ 513,135,543 $ 3,056,731 $ $ 516,192,274 aincludes common and convertible preferred stocks as well as other equity investments. b Includes securities determined to have no value at October 31, cfor detailed categories, see the accompanying Statement of Investments. franklintempleton.com Semiannual Report 43

45 NOTES TO FINANCIAL STATEMENTS (UNAUDITED) 11. Fair Value Measurements (continued) A reconciliation of assets in which Level 3 inputs are used in determining fair value is presented when there are significant Level 3 financial instruments at the beginning and/or end of the period. At October 31, 2017, the reconciliation of assets is as follows: Balance at Beginning of Period Purchases Sales Transfer Into Level 3 a Transfer Out of Level 3 Cost Basis Adjustments Net Realized Gain (Loss) Net Unrealized Appreciation (Depreciation) Balance at End of Period Net Change in Unrealized Appreciation (Depreciation) on Assets Held at Period End Franklin Biotechnology Discovery Fund Assets: Investments in Securities: Equity Investments: b Biotechnology $ 9,166,510 $2,799,992 $ (7,312,581) $4,813,486 $ $ $ 3,562,537 $ 583,871 $13,613,815 $ 975,092 Pharmaceuticals ,765,403 (6,380,617) (2,591,988) 1,330, ,735 (460,563) Escrows and Litigation Trusts.... 1,308,937 37,791 1,346,728 37,791 Total Investments in Securities. $16,931,913 $2,799,992 $(13,693,198) $6,122,423 $ $ $ 970,549 $1,952,599 $15,084,278 $ 552,320 Receivables: Investment Securities Sold. $ 9,126,475 $ $ $ $(9,381,849) $ $ $ 255,374 $ $ athe investments were transferred into Level 3 as a result of the unavailability of other significant observable valuation inputs. May include amounts related to a corporate action. bincludes common and preferred stocks as well as other equity investments. Significant unobservable valuation inputs for material Level 3 financial instruments and impact to fair value as a result of changes in unobservable valuation inputs as of October 31, 2017, are as follows: Description Fair Value at End of Period Valuation Technique Unobservable Inputs Amount/Range Impact to Fair Value if Input Increases a Franklin Biotechnology Discovery Fund Assets: Investments in Securities: Equity Investments: Biotechnology... $10,752,368 Discounted Cash Flow Free cash flow $ 75.9 / share Increase b All Other Investments c... 4,331,910 Total... $15,084,278 Discount for lack of marketability 2.1% % Decrease b Discount rate 10.0% Decrease b Probability rate 90.0% Increase b arepresents the directional change in the fair value of the Level 3 financial instruments that would result from a significant and reasonable increase in the corresponding input. A significant and reasonable decrease in the input would have the opposite effect. Significant impacts, if any, to fair value and/or net assets have been indicated. b Represents a significant impact to fair value but not net assets. cincludes financial instruments with values derived using prior transaction prices or third party pricing information without adjustment for which such inputs are unobservable. May also include fair value of immaterial financial instruments developed using various valuation techniques and unobservable inputs. 44 Semiannual Report franklintempleton.com

46 NOTES TO FINANCIAL STATEMENTS (UNAUDITED) 12. Subsequent Events The Funds have evaluated subsequent events through the issuance of the financial statements and determined that no events have occurred that require disclosure. Abbreviations Selected Portfolio ADR CPO American Depositary Receipt Certificate of Ordinary Participation (usually Mexico) franklintempleton.com Semiannual Report 45

47 Shareholder Information Proxy Voting Policies and Procedures The Trust s investment manager has established Proxy Voting Policies and Procedures (Policies) that the Trust uses to determine how to vote proxies relating to portfolio securities. Shareholders may view the Trust s complete Policies online at franklintempleton.com. Alternatively, shareholders may request copies of the Policies free of charge by calling the Proxy Group collect at (954) or by sending a written request to: Franklin Templeton Companies, LLC, 300 S.E. 2nd Street, Fort Lauderdale, FL 33301, Attention: Proxy Group. Copies of the Trust s proxy voting records are also made available online at franklintempleton.com and posted on the US Securities and Exchange Commission s website at sec.gov and reflect the most recent 12-month period ended June 30. Quarterly Statement of Investments The Trust files a complete statement of investments with the US Securities and Exchange Commission for the first and third quarters for each fiscal year on Form N-Q. Shareholders may view the filed Form N-Q by visiting the Commission s website at sec.gov. The filed form may also be viewed and copied at the Commission s Public Reference Room in Washington, DC. Information regarding the operations of the Public Reference Room may be obtained by calling (800) SEC Semiannual Report franklintempleton.com

48 This page intentionally left blank.

49 This page intentionally left blank.

50 Semiannual Report and Shareholder Letter Franklin Strategic Series Investment Manager Franklin Advisers, Inc. Distributor Franklin Templeton Distributors, Inc. (800) DIAL BEN / franklintempleton.com Shareholder Services (800) Authorized for distribution only when accompanied or preceded by a summary prospectus and/or prospectus. Investors should carefully consider a fund s investment goals, risks, charges and expenses before investing. A prospectus contains this and other information; please read it carefully before investing. To help ensure we provide you with quality service, all calls to and from our service areas are monitored and/or recorded Franklin Templeton Investments. All rights reserved. FSS2 S /17